



Vaccines and Global Health: The Week in Review
8 January 2022 :: Issue 638
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

::

Milestones - Perspectives

:: ***[Coronavirus \[COVID-19\] - WHO](#)***

:: ***[Emergencies](#)***

:: ***[Organization Announcements](#)***

:: ***[Journal Watch](#)***

Milestones - Perspectives



WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

6 January 2022 *Speech*

[WHO Director-General's opening remarks at the media briefing on COVID-19 - 6 January 2022](#)

Happy New Year! The dawn of a new year offers an opportunity to renew our collective response to a shared threat.

I hope global leaders who have shown such resolve in protecting their own populations will extend that resolve to make sure that the whole world is safe and protected. And this pandemic will not end until we do that!

Last week, I asked everyone to make a New Year's resolution to get behind the campaign to vaccinate 70% of people in every country by the middle of 2022. And on top of that, to ensure that breakthrough treatments, as well as reliable tests, are available in all countries. To end the acute stage of the pandemic, the highly effective tools science has given us need to be shared fairly and quickly with all countries of the world.

Vaccine inequity and health inequity overall were the biggest failures of last year. While some countries have had enough personal protective equipment, tests and vaccines to stockpile throughout this pandemic, many countries do not have enough to meet basic baseline needs or modest targets, which no rich country would have been satisfied with.

Vaccine inequity is a killer of people and jobs and it undermines a global economic recovery. Alpha, Beta, Delta, Gamma and Omicron reflect that in part because of low vaccination rates, we've created the perfect conditions for the emergence of virus variants. Last week, the highest number of COVID-19 cases were reported so far in the pandemic.

And we know, for certain, that this is an underestimate of cases because reported numbers do not reflect the backlog of testing around the holidays, the number of positive self-tests not registered, and burdened surveillance systems that miss cases around the world. While Omicron does appear to be less severe compared to Delta, especially in those vaccinated, it does not mean it should be categorized as 'mild'. Just like previous variants; Omicron is hospitalizing people and it is killing people. In fact, the tsunami of cases is so huge and quick, that it is overwhelming health systems around the world.

Hospitals are becoming overcrowded and understaffed, which further results in preventable deaths from not only COVID-19 but other diseases and injuries where patients cannot receive timely care. First-generation vaccines may not stop all infections and transmission but they remain highly effective in reducing hospitalization and death from this virus.

So as well as vaccination, public health social measures, including the wearing of well fitting masks, distancing, avoiding crowds and improving and investing in ventilation are important for limiting transmission. **At the current pace of vaccine rollout, 109 countries would miss out on fully vaccinating 70% of their populations by the start of July 2022.**

The essence of the disparity is that some countries are moving toward vaccinating citizens a fourth time, while others haven't even had enough regular supply to vaccinate their health workers and those at most risk. Booster after booster in a small number of countries will not end a pandemic while billions remain completely unprotected. But we can and must turn it around. In the short-term we can end the acute stage of this pandemic while preparing now for future ones.

First, we must effectively share the vaccines that are being produced.

Throughout most of 2021 this was not the case but toward the end, supply increased. Now it's crucial that manufacturers and dose-donating countries share delivery timings ahead of time so that countries have adequate preparation to roll them out effectively.

Second, let's take a 'never again' approach to pandemic preparedness and vaccine manufacturing so that as soon as the next generation of COVID-19 vaccines become available, they are produced equitably and countries don't have to beg for scarce resources. A few countries have provided a blueprint for how high quality vaccines and other health tools can be mass produced quickly and distributed effectively. And now we need to build on it. WHO will continue to invest in vaccine manufacturing hubs and work with any and all manufacturers who are willing to share know-how, technology and licenses. I'm encouraged by some of the vaccines currently going through trial where innovators have already committed to waiving patents and sharing licenses, technology and know how. It reminds me of how Jonas Salk did not patent his polio vaccine and in doing so saved millions of children from the disease.

Lets also invest and build the public health and health systems we need with strong surveillance, adequate testing, a strengthened, supported and protected health workforce, and an empowered, engaged and enabled global population.

And finally, I call on citizens of the world, including civil society, scientists, business leaders, economists and teachers to demand that governments and pharmaceutical companies to share health tools globally and bring an end to the death and destruction of this pandemic.

We need vaccine equity, treatment equity, test equity and health equity and we need your voices to drive that change.

Equity, equity, equity.

...

.....
.....

[Achieving 70% COVID-19 Immunization Coverage by Mid-2022](#)

Statement of the Independent Allocation of Vaccines Group (IAVG) of COVAX
23 December 2021

The Independent Allocation of Vaccines Group (IAVG) has issued a set of recommendations to make the allocation of COVID-19 vaccines more equitable and more effective. The group was established a year ago, to validate and assess vaccine allocations recommended by WHO's and Gavi's Joint Allocation Taskforce (JAT) of COVAX. [1] Since then, much has changed.

COVAX was envisioned to be the world's primary distributor of COVID-19 vaccines, with IAVG serving as an independent referee for needs-based allocations. **But rich nations largely sidestepped COVAX, hoarding doses for their own populations and cutting deals directly with low- and middle-income countries. This has made subsequent allocation decisions even more challenging.**

The IAVG is concerned that the primary priority use of available vaccines is not consistent with the goals outlined in the Strategy to Achieve Global COVID-19 Vaccination by Mid-2022 in October 2021. [2] **The group also notes that it has validated the allocation of only 730 million of the estimated 8 billion doses of vaccine that have been administered globally, which is less than 10%.** The rapid emergence of the Omicron variant is a stark reminder of the ongoing threat posed by the evolution of the COVID-19 pandemic and reinforces the critical need to achieve high levels of immunization coverage in all countries, including in highly vulnerable populations, in a timely manner.

The IAVG is therefore calling for:

:: Achievement of 70% coverage with COVID-19 vaccines in all countries as a global imperative.

As the overall vaccine supply to COVAX is anticipated to continue to grow substantially next year, COVAX will have a greater opportunity to contribute to achieving this goal. Manufacturers, vaccine-producing and high-coverage countries must prioritize vaccine equity and transparency, including the sharing of information about manufacturing capacity and supply schedules with COVAX, as well as vaccine access plans.

:: All countries to work with COVAX with considerable urgency to optimize the strategic use of the growing vaccine supply.

This means that high-coverage countries will need to establish complementary, "dual-track" approaches that consider both domestic and international goals.

Greater attention must be paid to who is being immunized. Equity must remain the overarching principle, and priority must be given in all countries to ensuring that the primary series is offered first and foremost to all adults and adolescents, in the step-wise manner recommended by the WHO, given that a high proportion of these populations still require primary immunization. However, as more is known about the required vaccination response in the face of Omicron, the need for booster doses and need to immunize children, the COVAX vaccine allocation decisions must consider these recommendations.

Given the global health and epidemiologic consequences of failing to immunize vulnerable populations, including those in humanitarian settings, the IAVG recommends that COVAX continue to work with all manufacturers and countries to immediately increase the availability and uptake of vaccines in these populations.

:: All countries to have a steady, predictable supply of COVID-19 vaccines, which meet the unique needs of each country. Attention must be paid to addressing prohibitive absorptive challenges in countries that request support.

This may include support for vaccine storage, distribution, administration and/or record-keeping, which may in part be due to competing health and immunization crises [3]. It will be important to have close collaboration between all COVAX partners, donors, and participants.

In order to increase demand for COVID-19 vaccines, ongoing, concerted global, national and local leadership is required to address vaccine misinformation.

Background

The initial COVAX targets were to achieve 3% coverage, and then 20% vaccine coverage through COVAX-secured doses by the end of 2021. [4] These targets were then expanded globally, when WHO released the Strategy to Achieve Global COVID-19 Vaccination by Mid-2022 in October 2021. [5] The new global target is 40% total population coverage by the end of 2021, and 70% total population coverage by mid-2022. However, these figures were from all country sources of supply, not solely from COVAX. COVAX would nonetheless contribute as much as possible to efforts to reach this coverage level in a fair and equitable manner.

None of these targets have been met. Ninety-eight countries have not vaccinated 40% of their population. An estimated 1.4 billion eligible people [6] need to be urgently immunized, many of whom are in the highest risk groups for death and serious illness.

These gaps have been most pronounced in low-and lower-middle income countries (LICs and LMICs), with 34 out of 89 Advanced Market Commitment (AMC) participants, [7] representing the countries that are most dependent on COVAX to access COVID-19 vaccines, not achieving the 40% target. The main reason for this has been the severe vaccine supply constraints to COVAX, which persisted until the last quarter of 2021. In the forthcoming months, larger volumes of vaccine are expected to become available, but in most cases the increase in volumes will create challenges in absorption capacity in resource-poor settings. This includes the capacity to receive, store, distribute, administer (due, for example, the lack of trained health personnel or vaccination centers), and to record vaccine use, including wastage.

Another hurdle in achieving the target of 70% total population coverage in all countries by mid-2022 will be demand limits arising from widespread misinformation and its resulting vaccine hesitancy.

Challenges

The COVAX portion of the global supply -

The original goal of COVAX was to achieve fair and equitable vaccine access across all 162 current Facility participants, and the initial role of the IAVG was to validate vaccine allocation decision (VAD) proposals that included all participants. Many high-income countries (HICs) entered into direct contractual arrangements with vaccine suppliers, bypassing the COVAX mechanism, and pharmaceutical companies did not prioritize and deliver according to their contractual obligations with COVAX, seriously reducing its supply and making it highly unpredictable.

Moreover, high-coverage countries began donating directly to their low-coverage and low-income counterparts, bypassing COVAX. Indemnity and liability-related conditions are added barriers to the vaccine access for the most vulnerable populations. The IAVG has validated the allocation of only 730 million of the estimated 8 billion doses of vaccine that have been administered globally, which is less than 10%.

Additionally, many of the donated doses channeled through COVAX have been earmarked for specific countries, compounding the challenge of achieving the goal of fair and equitable access among lower income countries.

With respect to vaccine allocation, the IAVG recommended and acknowledges that, where feasible, the limited COVAX supply has recently been dedicated to those countries with low estimated total population coverage which are likely relying solely on COVAX for access to COVID-19 vaccines.

Unpredictable supply to COVAX -

1) Procured doses - While those involved in vaccine allocation through COVAX have done their best to direct and redirect available doses, supply unpredictability has strained the system, frustrated participating countries and undermined the allocation decisions of the IAVG. Not all expected doses from COVAX advanced purchase agreements (APAs) have been honoured by vaccine producers according to contractual obligations.

2) Donated volumes - Similarly, promised donations by high-income countries have often been late to materialize or unpredictable. Unexpected additional vaccine allocation rounds have been undertaken after sudden announcements of vaccine availability through donations to COVAX. Worsening the challenge, these sudden donations have often included vaccines with brief expiry windows. These last-minute scrambles, a part massively increasing transaction costs, added considerable stress to already severely resource-strapped countries coping with many competing health and humanitarian crises, straining participants' ability to plan for the receipt and use of their allocated vaccines. Beyond logistics, the last-minute deliveries undermined countries' efforts to inform the general public about the vaccines and the communication needed to counteract the misinformation spread by social media.

This way of doing business is not acceptable and needs to end.

Across country and in-country inequity -

The Global COVID-19 Vaccination Strategy [8] clearly outlines the step-by-step process needed to achieve the immediate goal of minimizing deaths, severe disease and overall disease burden, and reducing the risk of new variants. Older adults and high-risk populations, all adults, and adolescents have been prioritized in a step-wise manner, while the broader scope of vaccine-use recommendations is still under consideration. For instance, 15 times [9] as many booster doses are currently being administered globally as are primary doses in LICs. In October, the WHO and many other concerned partners [10] noted that data from 119 countries suggest that by September 2021, two in five health and care workers (HCW) were vaccinated on average. But the differences across regions and economic groups remained stark. For instance, less than one in ten have been fully vaccinated in the African region while four in five have been vaccinated in 22 mostly high income countries.

The IAVG is concerned that the primary priority use of available vaccines is not consistent with the goals outlined the Strategy.

More supply but more unknowns -

Although the world is expected to have enough COVID-19 vaccine doses by mid-2022 to vaccinate 70% of the world's population with three doses, [11] uncertainties abound. These include the possible need for variant-specific vaccines, changes to vaccination policies, country preference for some products over others, the programmatic complexity of managing multiple products, and the need for better intelligence on country-level planning and execution.

The uncertainty of the required vaccination response to the Omicron variant will necessitate ongoing attention to achieving fairness and equity while requiring flexibility in vaccine allocation and supply management.

Highly vulnerable populations –

Our collective health security depends on the health security of all populations wherever they are, and whatever status they may have in individual countries. Among them, people residing in humanitarian settings (refugees, internally displaced persons) are at considerably increased risk of infection with COVID-19 [12] and should be covered by country vaccine allocations.

References

[1] <https://www.who.int/groups/iavg>

[2] https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf?sfvrsn=5a68433c_5

[3] <https://covid19gap.org/assets/publications/COVID-GAP-From-Airports-to-Arms.pdf>

[4] <https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility>

[5] https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf?sfvrsn=5a68433c_5

[6] <https://data.worldbank.org/indicator/SP.POP.0014.TO>

[7] For information on the COVAX Facility's different participant modalities, please see [here](#) for AMC Participants and [here](#) for SFP Participants.

[8] https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf?sfvrsn=5a68433c_5

[9] Coronavirus (COVID-19) Vaccinations - Statistics and Research - Our World in Data

[10] Ibid.

[11] https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf?sfvrsn=5a68433c_5

[12] <https://conflictandhealth.biomedcentral.com/articles/10.1186/s13031-020-00307-8>

.....

Independent Allocation of Vaccines Group (IAVG)

IAVG Terms of Reference: <https://www.who.int/groups/iavg/terms-of-reference>

IAVG Reports

The IAVG has issued 12 reports on decision made under its remit available here:

<https://www.who.int/groups/iavg>

IAVG Members [accessed 08 Jan 2022]

[Professor Anna Mia Ekström](#)

[Dr Arlene King](#)

[Christopher Maher](#)

[Dr Narendra Kumar Arora](#)

[Dr Bruce G. Gellin](#)


[Doctor Dafrossa Cyrily Lyimo](#)

[Professor Tjandra Aditama](#)


[Doctor Alejandro Cravioto](#)

Maria Guevara
 Dr Manica Balasegaram
 Dr Poh Lian Lim
 Dr Masahiko Hachiya

The Allocation Mechanism for vaccines interacts directly with the COVAX facility



The JAT and IAVG formulate a vaccine allocation decision, passed on to COVAX facility for implementation



1. The allocation would then be passed to UNICEF SD as supply coordinator, and PAHO RF and self-procuring participants 2. Algorithm can be checked/modified by JAT if required
 3. Exceptional operational adjustments by UNICEF SD and PAHO RF based on rules formulated by the JAT



[Joint Statement of the Multilateral Leaders Taskforce on Scaling Covid-19 Tools, December 17, 2021: “From Vaccines to Vaccinations”](#)

Washington, December 22, 2021 — The heads of the **International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization** held high-level consultations with Gavi and UNICEF on December 17, 2021 aimed at increasing the use of COVID-19 vaccines and other critical medical countermeasures in low-income (LIC) and lower middle-income (LMIC) countries and supporting countries to be better prepared, resourced, and ready to roll out vaccines.

We agreed on the urgency to accelerate vaccinations in LICs, where under 5% of the population is fully vaccinated, as well as in LMICs, where around 30% of the population is fully vaccinated. We agreed to work with countries to support and strengthen their national vaccination goals consistent with the global target to vaccinate 70% of the populations in all countries by mid-2022. The emergence of the Omicron variant underscores the vital need for fair and broad access to vaccines as well as testing, sequencing, and treatments to end the pandemic.

Addressing vaccine inequity, particularly in LICs, requires increasing the supplies of vaccines to COVAX and AVAT, encouraging LICs and LMICs to purchase additional vaccine doses, and enhancing country readiness to deploy vaccines. Furthermore, to facilitate trade flows to support the manufacturing and distribution of vaccines and other COVID tools, export restrictions must be rolled back and trade-facilitating measures must be put in place. Fully funding the ACT-A Accelerator’s Financing Framework would play an important role in narrowing these gaps and reaching the global target.

Some LICs and LMICs are facing serious challenges in vaccine deployment. Constraints related to storage, cold chain capacity, and trained vaccinators are exacerbated in some cases by doses arriving with short shelf lives and without adequate lead time and shortages in ancillary supplies (such as syringes, safety boxes, and dilutants), with challenges to plan and finance vaccination campaigns in a timely manner. As in wealthier countries, vaccine hesitancy is also an issue in some LICs and LMICs.

To address such challenges, we call on governments that have already achieved high coverage to:

- **fulfill their donation pledges as quickly as possible** to accelerate near-term deliveries to COVAX;
- **release manufacturers from contracts and options and implement delivery swaps**, so they can prioritize supply to COVAX, AVAT, and low-coverage countries.

We urge governments that have yet to achieve high vaccination coverage to:

- **contract additional doses immediately** through AVAT, COVAX, or bilaterally;
- **establish in-country surge capacity** to increase the rate of vaccine utilization as supplies increase; and
- **coordinate between health and finance authorities for making increased use of multilateral development banks’ resources** that are readily available for both vaccine purchase and deployment.

We call for better coordination among vaccine manufacturers, dose donating countries, COVAX, AVAT, and other partners to improve visibility on vaccine supply schedules and quality of supply for LICs and

LMICs, to support country-level planning and preparedness for turning vaccines into vaccinations. **Visibility on schedules along with adequate lead times and shelf lives of vaccines are critical for both equitable distribution as well as for recipient countries and their partners to prepare for in-country deployment.**

Growing volumes of COVID-19 vaccines are forecast to arrive in LICs and LMICs in the coming months. Close coordination amongst all stakeholders will be crucial to help provide countries with the assistance and necessary resources to increase their capacity to administer those doses. **In this regard, we welcome the recent appointment by UNICEF and WHO, in partnership with Gavi, of the Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery,** who will play an important key role in strengthening in-country vaccine deployment.

.....

[UNICEF and WHO, in partnership with Gavi, ask Ted Chaiban to serve as Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery](#)

Statement by UNICEF Executive Director Henrietta Fore

NEW YORK, 6 December 2021 – “I am pleased to announce that UNICEF and WHO, in partnership with Gavi, have asked Ted Chaiban, currently UNICEF Regional Director Middle East and North Africa, to serve as Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery. “This decision is an expression of our joint commitment to reinvigorate efforts to turn vaccines into vaccinations in low- and middle-income countries...

.....
.....

[Reflections on 2021 from CEPI CEO Dr Richard Hatchett](#)

21 Dec 2021

By Dr. Richard Hatchett

[Excerpts]

...Whatever its ultimate impact, I believe the emergence of Omicron will come to be seen as a watershed event in the unfolding of the pandemic. Policymakers and elected officials should pay close attention to what Omicron is telling us. It encapsulates both how far we have come, even since 2020, and how far we have yet to go. And it portends our future with COVID....

...But we must also use the momentum the pandemic has created to institutionalize and improve our new response capabilities and to drive the creation of new norms of collective action and accountability. The response to Omicron, in its positive aspects, exemplifies the ways in which we must be ready to respond to any future threat and the speed and seriousness with which we must act to counter it even as we perform our assessments and gather information. Omicron’s emergence also provided dramatic backlighting for, and helped propel, the Special Session of the World Health Assembly that convened the week of November 29 to begin deliberations on an international framework or convention on pandemic prevention, preparedness, and response. Developing such a framework or convention will require sustained diplomacy and likely take years but I am confident the effort will succeed and that the agreements achieved at the Special Session will come to be regarded as foundational.

CEPI will contribute to this momentum in the coming months as we begin to implement our CEPI 2.0 agenda. We have already announced seed funding for three programs under our Broadly Protective SARS-CoV-2 Vaccine initiative and will soon announce our first awards to support the development of Broadly Protective Betacoronavirus Vaccines. With Wellcome Leap, we are co-funding 17 different performers under an RNA Readiness and Response (R3) initiative that aims to increase exponentially the number of biologic products that can be designed, developed, and produced every year, reducing their costs and increasing equitable access; and to create a self-sustaining network of manufacturing facilities providing globally distributed, state-of-the-art surge capacity to meet future pandemic needs. In January, we will put out a call to begin the development of our vaccine libraries and issue a report laying out our thinking about how to achieve the 100-Day Mission – all in the lead-up to our March 2022 Global Pandemic Preparedness Summit, hosted by the government of the United Kingdom. The Summit will provide an opportunity for world leaders to demonstrate their support for epidemic and pandemic preparedness, the role research and development can play in enabling such preparedness, the institutional capabilities and norms we need to establish to achieve the 100-Day Mission, the value of collective action against common threats, and the overriding imperative to secure access for all to vaccines and other countermeasures....

...Jeremy Farrar, the Director of Wellcome, has said we may still be closer to the beginning of the pandemic than to its end. Our work through COVAX will and must continue. And I am sure that 2022 will present many unforetold challenges, just as 2021 did. But even as we rise to meet whatever 2022 throws at us, we must envision and work toward the future that we desire for the long term. And how do we accomplish that? A friend, a journalist, had the opportunity recently to travel to Oslo to attend the ceremony honoring his longtime friend and colleague Maria Ressa, who, with Dmitry Muratov, received the 2021 Nobel Peace Prize for her “efforts to safeguard freedom of expression, which is a precondition for democracy and lasting peace.” After my friend returned, he called her [Nobel Address](#) to my attention as an “important document for our times” (it is; I commend it to you all). Two statements in her Address have stuck with me:

...We are standing on the rubble of the world that was, and we must have the foresight and courage to imagine what might happen if we don't act now, and instead, create the world as it should be – more compassionate, more equal, more sustainable...

...Without facts, you can't have truth. Without truth, you can't have trust. Without trust, we have no shared reality, no democracy, and it becomes impossible to deal with our world's existential problems: climate, coronavirus, the battle for truth.

The first statement calls us to recognize our predicament and to have the courage to imagine and begin working towards a better future. The second reminds us of the conditions required for communities to flourish and to work together to tackle their greatest problems. Courage, foresight, imagination, facts, trust, and a shared reality: lacking these, it will be all but impossible to deal with the challenges ahead. But with them, we can do anything – we can move mountains.

.....
.....

Financial Times
06 January 2022
Covid-19 vaccines

[Covid vaccine makers face investor pressure over global access](#)

Asset managers call for pharma executive pay to be linked to equitable distribution of jabs

Drugmakers need to prioritise global access to Covid-19 vaccines and tie management pay to equitable distribution, a group of top international investors has said.

Asset managers Nomura, BMO and GAM are among 65 institutional investors that have written to leading pharmaceutical companies urging them "to make the global availability of vaccines part of the remuneration policy of managers and directors". The signatories represent more than \$3.5tn in assets under management.

"It is clear that currently a large part of the world population still does not have sufficient and equitable access to vaccines," the investors said in the letter, published on Thursday.

"A pandemic which remains out of control in many parts of the world is and should be at the top of our agenda as global investors, and also for governments and the companies in which we invest." The letter was sent to the boards of Pfizer, Moderna, AstraZeneca and Johnson & Johnson...

... Drugmakers should prioritise fulfilling contracts for vaccine access schemes Covax and African Vaccine Acquisition Trust "as a matter of urgency", the investors wrote, and provide transparency and clear monthly supply schedules to these distribution alliances as well as to low- and middle-income countries.

They added that companies should negotiate areas such as delivery swaps with countries that already have high coverage, and commit to greater expertise and technology transfer including licensing rights.

"Pharmaceutical companies have a duty to do their utmost on this but unfortunately we see that they are lagging behind. In addition, the business case is clear: new variants threaten the recovery of economies around the world," said Rogier Krens, chief investment officer of Achmea Investment Management, the Netherlands-based fund manager that co-ordinated the letter.

Achmea said it would vote against any executive pay packages that did not integrate these objectives. Voting policy among the other signatories may vary. Alex Rowe, portfolio manager at Japan-based Nomura Asset Management, said "prioritising access to vaccines over near-term profits is not only the right thing to do from an ethical standpoint, but the most sustainable long-term approach for these businesses".

He said this would help lower the risk of new variants developing and of any potential backlash against drugmakers "with regards to their role in limiting the impact on human life".

The emergence of the highly infectious Omicron coronavirus variant in southern Africa in November highlighted the consequences of failures to vaccinate vast swaths of the world's population. Global markets tumbled and many countries were forced to bring in new lockdown measures in an effort to halt the spread.

Most of the 65 investors that signed the letter hold small stakes in three of the biggest vaccine manufacturers: Moderna, BioNTech and Pfizer. The largest by some distance is a 0.3 per cent stake in

Pfizer held by Canada's BMO Global Asset Management, worth \$1.04bn, while Achmea's largest pharma holding is a 0.01 per cent stake in J&J valued at \$41.1m, according to S&P Capital IQ.



Financial Times

3 January 2022

Opinion

There is a good chance the global impact of coronavirus will ease

The editorial board

Omicron, by far the most contagious coronavirus variant to date, is so rampant around the world that it is easy to feel despondent about the prospects of the pandemic easing — let alone coming to an end — in 2022. But there are good reasons to think that Covid-19's toll on global health and its wider social and economic impact could wane this year, if governments and health authorities follow appropriate policies and if this volatile virus develops in the way that many scientists believe is most likely.

A debate is growing between those who think new pathogens such as Sars-Cov-2 tend to cause milder disease as time passes and those who say they are just as likely to evolve in a more virulent direction. Without taking sides, it is reasonable to conclude that the interaction between virus and the human immune system means that the more people acquire some protection against severe Covid-19 symptoms through vaccination or infection, the better the outlook. No conceivable descendant of Sars-Cov-2 could have enough mutations in the right places to escape fully the attentions of both antibodies and T-cells generated by prior exposure to an earlier variant.

The top priority is, therefore, to vaccinate the whole world — as it should have been for the past year. Unfortunately, Covid-19 vaccine inequity has never been greater, with just 10 per cent of the population in low-income countries having received at least one jab, according to the World Health Organization, while wealthy nations are rolling out third or even fourth shots. As the WHO says, with global vaccine production close to 1.5bn doses a month, there will be enough for these booster programmes to continue, while directing far more supplies to poorer countries than in 2021, through schemes such as Covax.

Although industrialised nations are justified in protecting their populations with boosters for adults and campaigns to extend vaccination to children, we cannot expect to keep jabbing people every four to six months for very long in the face of new variants. We will have to rely on the immunity provided by annual inoculations — preferably with a new generation of products that are effective against all coronavirus variants — and by repeated exposure to what will sooner or later become an endemic infection.

Governments and regulators must encourage the development of new vaccine technologies to supplement the near duopoly that Moderna and BioNTech/Pfizer enjoy in the developed world with their mRNA products. At the same time, more investment should be directed towards antiviral drugs that could play a bigger role in suppressing symptoms in those who are infected. Recommended Covid-19 vaccines Covid-19 vaccine tracker: the global race to vaccinate

Another vital area that must be reinforced is diagnosis and surveillance. Requirements here range from ensuring enough quick lateral flow tests are available for people to check whether they are infected

before meeting others to building up more genomic sequencing capacity worldwide to monitor the emergence of new variants.

Whatever slim chance we might have had at the beginning of 2020 to eliminate Covid-19 has long gone. Efforts to control the pandemic have been justified so far in the context of a global health emergency but they cannot continue indefinitely. The collateral damage — to mental health and wellbeing, social cohesion and the global economy — would be too great. This year the world will have to build up resilience so that we can live with Sars-Cov-2 and its descendants, in a way that causes less disruption while still protecting those who are most vulnerable.

.....
.....

Editor's Note:

We recognize that the collection of JAMA Viewpoints below are largely focused on U.S. pandemic response policy, programs and imperatives.

JAMA

Online January 6, 2022

Viewpoint

[A National Strategy for the "New Normal" of Life With COVID](#)

Ezekiel J. Emanuel, MD, PhD; Michael Osterholm, PhD, MPH; Celine R. Gounder, MD, ScM
free access

JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24282

This Viewpoint discusses how US policy makers should address how the nation can move forward as the pandemic persists.

...Conclusions

After previous infectious disease threats, the US quickly forgot and failed to institute necessary reforms. That pattern must change with the COVID-19 pandemic. Without a strategic plan for the "new normal" with endemic COVID-19, more people in the US will unnecessarily experience morbidity and mortality, health inequities will widen, and trillions will be lost from the US economy. This time, the nation must learn and prepare effectively for the future.

The resources necessary to build and sustain an effective public health infrastructure will be substantial. Policy makers should weigh not only the costs but also the benefits, including fewer deaths and lost productivity from COVID-19 and all viral respiratory illnesses. Indeed, after more than 800 000 deaths from COVID-19, and a projected loss of \$8 trillion in gross domestic product through 2030,⁸ these interventions will be immensely valuable.

Viewpoint

[A National Strategy for COVID-19 Testing, Surveillance, and Mitigation Strategies](#)

David Michaels, PhD, MPH; Ezekiel J. Emanuel, MD, PhD; Rick A. Bright, PhD
free access

JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24168

This Viewpoint discusses the areas on which the US needs to improve its public health infrastructure in order to reduce COVID-19 transmission and achieve a "new normal": testing, surveillance, masking, and ventilation.

... Conclusions

To reduce COVID-19 transmission, achieve and sustain a “new normal,” and preempt future emergencies, the nation needs to build and sustain a greatly improved public health infrastructure, including a comprehensive, permanently funded system for testing, surveillance, and mitigation measures that does not currently exist.

Viewpoint

[A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics](#)

Luciana L. Borio, MD; Rick A. Bright, PhD; Ezekiel J. Emanuel, MD, PhD

free access

JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24165

This Viewpoint proposes a multistep plan that US can implement to achieve a “new normal” of living, in which the combined risk of all viral respiratory illnesses, including COVID-19, does not exceed the risk during prepandemic years.

...Conclusions

There has been tremendous progress in rapidly creating novel COVID-19 vaccines and therapeutics. Nevertheless, these efforts have been insufficient to achieve a “new normal,” in which the combined risk of all viral respiratory illnesses, including COVID-19, does not exceed the risk during pre-COVID-19 years. The US needs investment in variant-specific vaccines, alternative vaccine administration mechanisms, and research into the optimal vaccination strategies. Having effective vaccines are of real value in reducing the spread of COVID-19 and serious illness, but their benefits will be limited without near universal coverage. This coverage can be augmented through additional vaccination requirements. Finally, research needs to be expedited to develop and use effective COVID-19 oral therapeutics. The short window for administration requires a much closer linkage between COVID-19 testing and treatment.

Viewpoint

[The First 2 Years of COVID-19 - Lessons to Improve Preparedness for the Next Pandemic](#)

Jennifer B. Nuzzo, DrPH, SM; Lawrence O. Gostin, JD

free access

JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24394

This Viewpoint examines the lessons that the COVID-19 pandemic can provide public health institutions and health care personnel to advance preparedness, detection, and response regarding future pandemics.

Viewpoint

[The Pandemic Preparedness Program - Reimagining Public Health](#)

Eli Y. Adashi, MD, MS; I. Glenn Cohen, JD

free access

JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.23656

This Viewpoint reviews the leading objectives of the pandemic preparedness proposal, discusses the outcome of comparable past federal efforts, and emphasizes the imperative of intragovernmental coordination.

.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

Weekly Epidemiological and Operational updates

Last update: 08 Jan 2022

Confirmed cases :: 298 915 721
Confirmed deaths :: 5 469
Vaccine doses administered: 9 118 223 397

.....


[Weekly epidemiological update on COVID-19 - 06 January 2022](#)

Overview

During the week 27 December 2021 to 2 January 2022, following a gradual increase since October, the global number of new cases increased sharply by 71% as compared to the previous week, while the number of new deaths decreased by 10%. This corresponds to just under 9.5 million new cases and over 41 000 new deaths reported during the last week. As of 2 January, a total of nearly 289 million cases and just over 5.4 million deaths have been reported globally.

All regions reported an increase in the incidence of weekly cases, with the Region of the Americas reporting the largest increase (100%), followed by the South-East Asia Region (78%) and the European Region (65%). The African Region reported a weekly increase in the number of new deaths (22%), while all the other regions reported a decrease as compared to the previous week.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 2 January 2022**



**See [Annex 1: Data, table, and figure notes](#)

.....


[Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021](#)

[Full scale view available at title link above]

Status of COVID-19 vaccines within WHO EUL/PLU evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Mibe (Dermapharm) Germany (DP) – Delpharm, Saint-Remy FRANCE (DP) – Sanofi-Aventis Deutschland GmbH Germany (DP) – Siegfried Hameln GmbH, Germany (DP) – Patheon Italia S.p.A, Italy (DP) Diluent suppliers: – Pfizer Perth, Australia – Fresenius Kabi, USA – Pfizer Manufacturing Belgium Shelf life extension: 09 months at -70 to -90°C Booster dose approved for adults 18 years of age and older	31/12/2020
			USFDA		✓	Finalized: – Pharmacia & Upjohn, Kalamazoo (DP)PGS McPherson (DP) – Exelead, Inc. Indianapolis USA	16/07/2021 16/07/2021 30/09/2021		
2.	 AstraZeneca, AB	AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
			MFDS KOREA		Finalized	15 Feb 2021			
			Japan MHLW/PMDA		Finalized	09 July 2021			
			Australia TGA		Finalized	09 July 2021			
			COFEPRIS (Mexico) ANMAT (Argentina)		Finalized	23 December 2021			
			Additional sites: – SK-Catalent – Wuxi (DS) – Chemo Spain – Amylin Ohio US (DP)		16 April 2021 30 April 2021 04 June 2021 23 July 2021				
Additional site: Nipro Pharma Corporation Ise, Japan	11 October								
Additional site: Siam Bioscience Co., Ltd Thailand	11 October 2021								

Vaccines **Guidance Document 23 December 2021**

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
7.	 Serum Institute of India Pvt. Ltd	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized DS and DP Manjari Bk Pune	15 Feb 2021 12 Nov 2021
8.	 Janssen-Cilag International NV	Ad26.COV2.5	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites)	12 March 2021
			DCGI		Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein mRNA based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Additional sites: Finalized – Aspen RSA (DP) – Catalent Agnani Italy (DP) – Grand River Aseptic Manufacturing Inc., USA – MSD (Merck), West Point/PA, USA (DP) – Merck, Durham, UK (DS) – Ongoing
9.	 Moderna Biotech	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021
			USFDA		Finalized ModernaTx, Norwood (DS) – Catalent Indiana, LLC (DP) – Lonza Biologics, Inc. Portsmouth, USA (DS) – Baxter, Bloomington, USA (DP)	06 August 2021			
			MFDS		Finalized	23 December 2021			
10.	 Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC after ongoing inspection
11.	 Sinovac Life Sciences Co., Ltd. Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 dose presentation	01 June 2021 30 September 2021
12.	 Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	✓	Finalized	03 November 2021
13.	 Serum Institute of India Pvt. Ltd.	NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓	Rolling data started 21 September 2021	Finalized	17 December 2021
14.	 Novavax	NVX-CoV2373/Nuvaxovid	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓	Rolling data started 19 August 2021	Finalized	20 December 2021
15.	 Russian Direct Investment Fund	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
16.	 Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed
17.	 武汉生物 Wuhan Institute of Biological Products	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing	TBC
18.	 SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓	✓	Rolling data started 30 July 2021	Ongoing	TBC
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data started 20 September	Ongoing	
20.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓	2 Pre-submission meeting held on 1 and 21 Dec 2021			
21.	 LIFESCIENCES	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: C/nCoV/COV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Application withdrawn by manufacturer			
22.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus, Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminium	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd
* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.
**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant; 4. Risk-benefit decision 5. Final decision made
*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

Please send any questions you may have to: WHOEU@who.int

.....

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases

[Vaxzevria significantly boosted antibody levels against Omicron](#)

23 December 2021

:: University of Oxford study supports use of Vaxzevria as third dose booster against Omicron
 :: Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

[Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities](#)

23 December 2021

:: University of Oxford study supports use of Vaxzevria as third dose booster against Omicron
 :: Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Bharat Biotech

Press Releases

Jan 08: [COVAXIN® \(BBV152\) booster dose study shows promising results](#)

The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated long-term safety with no serious adverse events.

BioCubaFarma – Cuba

Últimas Noticias

[Casi el 70% de la población cubana ya ha sido inmunizada contra la COVID-19.](#)

20 de Diciembre, 2021

CanSinoBIO

News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China

News

Jan 5, 2022 [**Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA**](#)

Jan 5, 2022 [**Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai**](#)

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases

Jan 06, 2022 *United States*

[**Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States**](#)

Dec 30, 2021 *United States*

[**Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant**](#)

Separate analysis showed Johnson & Johnson COVID-19 vaccine booster generated 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against Omicron

Moderna

Press Releases

January 5, 2022

[**Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus \(EBV\) Vaccine**](#)

December 27, 2021

[**Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna's COVID-19 Vaccine or Updated Booster Candidate in 2022**](#)

December 27, 2021

[**Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022**](#)

December 20, 2021

[**Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant**](#)

Novavax

Press Releases

[**Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine**](#)

Dec 31, 2021

[**Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India**](#)

Dec 28, 2021

[**Novavax and SK bioscience Expand Manufacturing Agreement**](#)

Dec 23, 2021

[**Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies**](#)

Dec 22, 2021

[**Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study**](#)

Dec 21, 2021

[**World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine**](#)

Dec 21, 2021

[**World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine**](#)

Dec 20, 2021

Pfizer

Recent Press Releases

01.05.2022

[**Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine**](#)

01.04.2022

[**Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19**](#)

01.04.2022

[**Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference**](#)

01.03.2022

[Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older](#)

12.22.2021

[Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment](#)

12.22.2021

[Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19](#)

Sanofi Pasteur

Press Releases

December 15 2021 *Press releases*

[Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation](#)

Serum Institute of India

NEWS & ANNOUNCEMENTS

Tuesday, December 28, 2021

[Serum Institute of India and Novavax Receive Emergency Use Authorization in India for COVOVAX™ ...](#)

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases

[SINOVAC CoronaVac® Shows Good Safety in Pregnant and Postpartum Women](#)

2021/12/29

[South Africa Phase III Clinical Study Shows SINOVAC CoronaVac® Safe for Children as Young as 6 Months](#)

2021/12/2

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

Merck

News releases

December 24, 2021

[Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan](#)

December 23, 2021

[Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19](#)

December 22, 2021

[Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir](#)

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases

[SK bioscience-Novavax Extend Collaboration and Contract Manufacturing Agreements of COVID-19 Vaccine](#)

SK-Novavax amended the Collaboration and License agreement for contract manufacturing of 'NVX-CoV237...

2021. 12. 24

Valneva

Press Releases

January 5, 2022

[Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001](#)

December 23, 2021

[Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate](#)

.....
.....

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 08 Jan 2022](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



31

vaccines approved for use by at least one national regulatory authority¹



10

vaccines in WHO's Emergency Use Listing



20.6bn

doses secured globally



\$2-\$40

reported vaccine price range per dose



5.52bn

doses COVAX has secured, optioned, or received as donations



966.6M

doses shipped through COVAX to 144 countries

.....

.....

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Targets and Overview of Progress [undated]

		LIC	LMIC	UMIC	HIC	World
Vaccines						
Secure Vaccines to Cover 70% of the Population	% of Countries with Procurement Gap	63	35	33	5	29
Secure Vaccines to Cover 70% of the Population	Gap (Mn Doses)	103	120	52	1	276

Alignment of Targets

Overview of Gaps

	MLT / IMF Pandemic Proposal	ACT-A	US Global C19 Summit	Alignment
Vaccines	At least 40% coverage in all countries by end-2021 and 70% by mid-2022			Aligned
Diagnostics	One test per 1000 people per day by the end of 2021 in all countries			Aligned
Treatments (incl. O2)	Treat all new cases.	All 200 mn new cases are treated.	Making oxygen readily accessible for inpatient health facilities in all countries.	Broadly Aligned
PPE	All essential healthcare workers are protected.	All 10 mn essential HWs are protected.	Access to PPE for all LIC/LMIC healthcare workers in 2021, with surge capacity available for every region in 2022.	Broadly Aligned

Sources: IMF Staff Discussion Note - A Proposal to End the COVID-19 Pandemic, Multilateral Leaders Task Force on COVID-19 website, ACT-A Strategic Plan & Budget, and Fact Sheet: Targets for Global COVID-19 Summit.



Duke – Launch and Scale Speedometer

[The Race for Global COVID-19 Vaccine Equity](#)

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)



[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.





Data updated on Jan 7th 2022



Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 08 Jan 2022]: <https://data.undp.org/vaccine-equity/>
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

08 Jan 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 299M total confirmed cases; 5.5M total confirmed deaths

Global vaccines administered: 9.40B

Number of Countries: 30 [30 week ago]

COVAX Allocations Round 4-9 (Number of Doses): 220M

COVAX Delivered (Number of Doses): 260M

Other Delivered (Number of Doses): 330M

Total Delivered (Number of Doses): 590M

Total Administered (Number of Doses): 450M

.....
.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]


<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **08 Jan 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





.....

Our World in Data


Coronavirus (COVID-19) Vaccinations [Accessed 08 Jan 2022]

- :: [59.1%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- :: [9.4 billion doses](#) have been administered globally, and [29.8 million](#) are now administered each day.
- :: Only [8.9%](#) of people in low-income countries have received at least one dose.

Share of the population fully vaccinated against COVID-19, Jan 7, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 8 January 2022, 10:00 (London time)
 Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
 OurWorldInData.org/coronavirus • CC BY


▶ Dec 13, 2020 ○ Jan 7, 2022

Share of the population fully vaccinated against COVID-19, Jan 7, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 8 January 2022, 10:00 (London time)
 Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
 OurWorldInData.org/coronavirus • CC BY

▶ Dec 13, 2020 ○ Jan 7, 2022

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

FDA

Press Announcements

[January 7, 2022 - Coronavirus \(COVID-19\) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months](#)

[January 3, 2022 - Coronavirus \(COVID-19\) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine](#)

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

No meetings on [calendar](#)

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

January 05, 2022 *Press Briefings*

[Remarks by President Biden Before Meeting on COVID-19](#)

January 04, 2022 *Speeches and Remarks*

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Notes

Media Note

[International Travel Challenges During COVID-19](#)

December 30, 2021

Readout

[Secretary Blinken’s Virtual Meeting with Foreign Ministers Regarding the Omicron Variant](#)

December 21, 2021

Press Statement

[Supporting Multilateral Responses to the COVID-19 Crisis](#)

Antony J. Blinken December 21, 2021

The United States is providing an additional \$580 million from the American Rescue Plan Act to support seven partners who are working tirelessly in our global fight against COVID-19. This funding includes:

- **\$280 million for the World Health Organization (WHO)**, including \$50 million for the Contingency Fund for Emergencies, to help contain the spread of COVID-19, particularly through surveillance and laboratory testing, and support the continuity of essential health services and systems, especially for individuals most at risk;
- **\$170 million to the United Nations Children’s Fund (UNICEF)** to expand its efforts to deliver COVID-19 vaccines around the world including to high-risk and vulnerable populations, provide critical COVID-19 commodities, such as Personal Protective Equipment and oxygen equipment, and support education needs in response to the COVID-19 pandemic;
- **\$75 million to the Pan American Health Organization (PAHO)** to provide technical cooperation to support implementation and monitoring of COVID-19 vaccinations in the Americas;
- **\$20 million to the United Nations Development Program (UNDP)** to help address the socioeconomic impact of COVID-19, including through programs for providing employment services and livelihood support;
- **\$20 million for the United Nations Population Fund (UNFPA)** to support its efforts to protect health workers and provide women with safe reproductive and maternal health care to mitigate higher rates of maternal and neonatal mortality and morbidity related to COVID-19;
- **\$10 million to the Food and Agriculture Organization (FAO)** to support its efforts to improve health surveillance, early warning, and risk assessment tools for zoonotic diseases; and
- **\$5 million to UN Women** to assist their efforts to support women and girls, in all their diversity, during the COVID-19 crisis, including a focus on programs to prevent and respond to gender-based violence.

.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases •

[News: EMA recommends Nuvaxovid for authorisation in the EU \(new\)](#)

CHMP, Last updated: 20/12/2021

EMA has recommended granting a [conditional marketing authorisation](#) for Novavax’s COVID-19 vaccine Nuvaxovid (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age.

[News: New treatment for sickle cell disease \(new\)](#)

CHMP, Last updated: 17/12/2021

[News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 13-16 December 2021 \(new\)](#)

CHMP, Last updated: 17/12/2021

...The monoclonal antibody Xevudy (sotrovimab) received a positive opinion from the Committee for the treatment of COVID-19. More details are available in a [separate news announcement](#)..

...The CHMP gave a positive opinion for Apexxnar (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) as prophylaxis against pneumococcal pneumonia and associated invasive disease...

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

News

[ECDC updates its guidance regarding quarantine and isolation considering the rapid spread of Omicron in the EU/EEA](#)

News story - 7 Jan 2022

Considering the rapid spread of the Omicron variant of concern (VOC), ECDC is proposing options regarding quarantine and isolation, and recommendations that can be adapted and implemented by EU/EEA Member States when resources are limited and when there is high pressure on healthcare systems and other functions in society (e.g. staff shortage and reduced resources). Due to limited scientific evidence on the epidemiological characteristics of Omicron, the proposed options are not evidence based and may imply an additional risk for transmission.


News

[Weekly epidemiological update: Omicron variant of concern \(VOC\) – week 1 \(data as of 7 January 2022\) EU/EEA](#)

Epidemiological update - 7 Jan 2022

Over the past two weeks, a steep increase in COVID-19 notification rates has been observed in several EU/EEA countries.

.....



Accessed 08 Jan 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Statement 6 January 2022

[Statement by President von der Leyen on vaccine sharing in 2021 and targets for 2022](#)

The European Union is the biggest donor of safe and effective COVID-19 vaccines so far. As Team Europe we have exceeded our vaccine-sharing target in 2021.

We promised to share 250 million doses with low and middle income countries by the end of 2021. And in fact we shared 380 million doses, mostly through COVAX.

More than 255 million of these doses were already delivered to recipient countries. And we will do more.

The Team Europe has promised to share 700 million doses by mid-2022. We are on track to fulfill this promise.

In particular, we will step up our efforts to support Africa where vaccination rates are lower than in other parts of the world.

Because we will only control this global pandemic if we fight it in every corner of the world.

Press release 23 December 2021

[**EU and US officials discuss efforts to donate and deliver 1.7 billion vaccine doses around the world by mid-2022**](#)


Press release 22 December 2021

[**Rule of Law: Commission launches infringement procedure against Poland for violations of EU law by its Constitutional Tribunal**](#)

Today, the European Commission has decided to launch an infringement procedure against Poland because of serious concerns with respect to the Polish Constitutional Tribunal and its recent case law.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment





Accessed 08 Jan 2022. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[The one-shot Sputnik Light vaccine authorized in Tunisia as a universal booster](#)

Press release, 29.12.2021

[A study by the Gamaleya Center published at MedRxiv preprint server shows Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to Omicron variant of COVID](#)

Press release, 22.12.2021

[Venezuela received 7 mn doses of Sputnik Light booster in the biggest one-time global delivery of the one-shot Russian vaccine](#)

Press release, 21.12.2021

.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare


<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
 08 January 2022, 08:00
 IST (GMT+5:30)

(↑ Status change since
 yesterday)



COVID-19 Vaccination
 as on : 08 January
 2022, 08:00 IST
 (GMT+5:30)



07.01.2022 [Revised Guidelines for International Arrivals dated 7th January 2022](#)

07.01.2022 [List of Countries to be referred to in context of 'Guidelines for international arrivals' dated 7th January 2022](#)

07.01.2022 [Algorithm for revised guidelines for international arrivals 7th January 2022](#)

Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 358

:: More than 2 Cr Vaccine Doses administered among Adolescents between 15-18 age group

:: Schedule for 'precaution' dose of Covid-19 released today

:: India's cumulative vaccination coverage achieves 151.47 crore

:: More than 79 lakh Vaccine doses administered today till 7 pm

Posted On: 08 JAN 2022 8:37PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

No new regulatory/deployment action identified.

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 05 January 2022

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

– **Madagascar:** One cVDPV1 positive environmental sample

.....
.....

Disease Outbreak News (DONs)

23 December 2021 | Yellow Fever - West and Central Africa

23 December 2021 | Hepatitis E Virus – Republic of South Sudan

.....

.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[**Afghanistan crisis**](#) *[Last apparent update: 18 Oct 2021]*

[**Crisis in Northern Ethiopia**](#) *[Last apparent update: 1 June 2021]*

[**Ebola outbreak, Democratic Republic of the Congo, 2021**](#) *[Last apparent update: 17 Aug 2021]*

[**Ebola outbreak outbreak, N'Zerekore, Guinea, 2021**](#) *[Last apparent update: 17 Aug 2021]*

[**Coronavirus disease \(COVID-19\) pandemic**](#) *[See COVID above]*

[**Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020**](#)

[Last apparent update: 17 Aug 2021]

[**Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020**](#)

[Last apparent update: 17 Aug 2021]

[**Ebola outbreak, Democratic Republic of the Congo, 2018**](#) *[Last apparent update: 24 July 2018]*

[**Yemen crisis**](#) *[Last apparent update: 12 February 2021]*

[**Syria crisis**](#) *[Last apparent update: 18 June 2021]*

[**Somalia crisis**](#) *[Last apparent update: 24 March 2018]*

[**Nigeria crisis**](#) *[Last apparent update: 1 Oct 2021]*

[**Ebola outbreak, Democratic Republic of the Congo, 2017**](#) *[Last apparent update: 17 Aug 2021]*

[**Zika virus disease outbreak, 2015-2016**](#) *[Last apparent update: 24 Jan 2020]*

[**Ebola outbreak: West Africa, 2014-2016**](#) *[Last apparent update: 17 Aug 2021]*

[**Iraq crisis**](#) *[Last apparent update: 9 Jan 2008]*

[**South Sudan crisis**](#) *[Last apparent update: 23 Sep 2020]*

[**Avian influenza A \(H7N9\) virus outbreak**](#) *[Last apparent update: 13 September 2021]*

[**Middle East respiratory syndrome \(MERS-CoV\) outbreak**](#) *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Afghanistan

- [Afghanistan: ICCT Real-Time Response Overview Situation Report \(23 December 2021\)](#)

Northern Ethiopia

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 6 January 2022](#)

Situation Report

HIGHLIGHTS

- In Amhara, 30 hospitals, 280 health centres and 890 health posts have resumed provision of basic health services.
- Food Cluster partners voiced concern over the risk of spoilage and infestation of humanitarian food stocks in Semera, Afar Region, due to the harsh weather conditions and the urgent need to bring in fumigants (currently unavailable in the region) to treat stored stock.
- As of 3 January, food partners have around only 10000L of fuel left in Tigray. At least 60000L of fuel are needed to dispatch around 4000 MT of food currently available in Mekelle.
- **A measles campaign started on 1 January in Mekelle, targeting 1.7 million children under five years of age.**

.....

.....

WHO & Regional Offices [to 08 Jan 2022]

<https://www.who.int/>

Selected News, Statements

23 December 2021

Departmental news

[Achieving 70% COVID-19 Immunization Coverage by Mid-2022](#)

[See Perspectives above for full text]

22 December 2021

Statement

[Interim statement on booster doses for COVID-19 vaccination](#)

22 December 2021

News release

[From vaccines to vaccinations: seventh meeting of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics](#)

21 December 2021

Departmental news

[US FDA approved cabotegravir extended-release – the first long-acting injectable option for HIV pre-exposure prophylaxis](#)

21 December 2021
Departmental news

[WHO lists 10th COVID-19 vaccine for emergency use : Nuvaxovid](#)

20 December 2021
Departmental news

[Latest child mortality estimates reveal world remains off track to meeting Sustainable Development Goals](#)

20 December 2021
Departmental news

[Novavax Covid-19 vaccine recommendations for use](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [Meningitis outbreak in Democratic Republic of the Congo declared over](#) 24 December 2021

WHO Region of the Americas PAHO

:: 29 Dec 2021 [COVID-19 cases increase 50% in the Americas in the last week](#)

The region reports the biggest rise in cases worldwide with holiday period set to drive up numbers, PAHO warns, urging countries to continue vaccination campaigns and implementation of public health measures. Washington, DC, December 29, 2021 (PAHO)- Pan American Health Organization (PAHO) data show that COVID-19 cases increased 50% and deaths 11...

:: 23 Dec 2021 [PAHO welcomes first WHO emergency use listing of COVID-19 vaccine produced in Latin America](#)

Approval will increase vaccine availability as pandemic persists Washington, D.C., 23 December 2021 (PAHO) – The Pan American Health Organization (PAHO) welcomed the WHO listing today of an AstraZeneca vaccine jointly produced by Argentina and Mexico – the first such decision for a COVID-19 vaccine manufactured in Latin America. The vaccine,...

WHO South-East Asia Region SEARO

:: 8 January 2022 [News release Strict implementation of public health and social measures a must to arrest the surge: WHO](#)

WHO European Region EURO

No new digest content identified

WHO Eastern Mediterranean Region EMRO

:: [German donation supports nationwide monitoring of COVID-19 variants in Islamic Republic of Iran](#)
6 January 2022

:: [Statement by WHO's Regional Director for the Eastern Mediterranean on COVID-19](#)

Cairo, 22 December 2021 - A year ago, the COVID-19 vaccine rollout had brought us hope that we could end the acute phase of the pandemic by the end of 2021. Instead, as we enter the third year of

the pandemic, the world remains very much in its grip. Globally, COVID-19 has so far claimed more than five million lives...

[::Inequitable COVID-19 vaccination coverage in the Eastern Mediterranean Region is a missed opportunity to protect people from severe disease and death](#)

Cairo, 20 December 2021– As 2021 comes to an end, the gap in COVID-19 vaccination coverage between countries of the Eastern Mediterranean Region widens alarmingly. As of 14 December 2021, over 500 million doses of COVID-19 vaccine have been administered in the Region, an average of 65 doses per 100 population. However, high- and upper-middle-income countries have administered about twice the...

WHO Western Pacific Region

No new digest content identified

.....

WHO Events

<https://www.who.int/news-room/events/2>

[Selected]

19 January 2022

[Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization \(SAGE\) – 19 January 2022](#)

13 January 2022

[Seventh meeting of the WHO Council on the Economics of Health for All](#)

11 January 2022

[COVID-19 Case Management Webinar Series: COVID-19 and pregnancy](#)

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

6 January 2022

[Mekong Malaria Elimination: epidemiology summary, volume 15, July–September 2021](#)

30 December 2021

[Together on the road to evidence-informed decision-making for health in the post-pandemic era: a draft call for action](#)

Overview

The EVIPNet Call for Action for sustainable evidence-policy-society-systems was launched at the WHO Global Evidence-to-Policy Summit in November 2021, and received wide encouragement and support from global partners, multisectoral stakeholders and EVIPNet members. Existing EVIPNet country teams and partner organizations will provide additional support taking the Call for Action forward.

23 December 2021

[An implementation guide for the management of COVID-19 on board cargo ships and fishing vessels](#)

22 December 2021

[**WHO recommendations on mask use by health workers, in light of the Omicron variant of concern: WHO interim...**](#)

22 December 2021

[**COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December...**](#)

20 December 2021

[**Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19**](#)

20 December 2021

[**Annexes to the interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19**](#)

.....
.....
.....

CDC/ACIP [U.S.] [to 08 Jan 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[**Telebriefing on COVID-19 Update**](#) Friday, January 7, 2022

[**CDC Media Telebriefing: Update on COVID-19**](#) Thursday, January 6, 2022

[**CDC Reports Increase in Human Rabies Cases Linked to Bats in the U.S.**](#) Thursday, January 6, 2022

[**CDC Expands Booster Shot Eligibility and Strengthens Recommendations for 12-17 Year Olds**](#) Wednesday, January 5, 2022

[**CDC Recommends Pfizer Booster at 5 Months, Additional Primary Dose for Certain Immunocompromised Children**](#) Tuesday, January 4, 2022

[**CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population**](#) Monday, December 27, 2021

.....

[**ACIP Meetings**](#)

Next Meeting - January 12, 2022, 10:00am – 3:30pm Eastern

This meeting is virtual. No registration is required to watch the webcasts.

:: [Draft Agenda – January 12, 2022pdf icon](#)

:: [Webcast Link](#)

:: [Federal Register](#)

Presentation Slides

ACIP past meeting presentations: [January 5, 2022](#)

.....

[MMWR News Synopsis Friday, January 7, 2022](#)

Selected Content

:: [Risk Factors for Severe COVID-19 Outcomes Among Persons Aged \$\geq 18\$ Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021](#)

:: [Previously Released: Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021](#)

.....

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

1/7/22 [EARLY RELEASE: Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 years — United States, March 1, 2020–June 28, 2021](#)

1/7/22 [EARLY RELEASE: Effectiveness of BNT162b2 \(Pfizer-BioNTech\) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021](#)

1/7/22 [Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 07 Jan 2022 06:00:00 EST](#)

1/7/22 [COVID-19 Vaccine Booster Shot](#)

1/7/22 [COVID-19 Vaccines for Moderately to Severely Immunocompromised People](#)

1/7/22 [Staffing Resources](#)

1/7/22 [Information about the Moderna COVID-19 Vaccine](#)

1/7/22 [Different COVID-19 Vaccines](#)

1/7/22 [Infection Prevention and Control Assessment Tool for Nursing Homes Preparing for COVID-19](#)

1/7/22 [COVID Data Tracker Weekly Review](#)

1/6/22 [CDC Media Telebriefing: Update on COVID-19](#)

1/6/22 [Risk Factors for Severe COVID-19 Outcomes Among Persons Aged \$\geq 18\$ Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021](#)

1/6/22 [Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021](#)

1/6/22 [Overview of COVID-19 Isolation for K-12 Schools](#)

1/6/22 [Overview of COVID-19 Quarantine for K-12 Schools](#)

1/6/22 [Responding to COVID-19 Cases in K-12 Schools: Resources for School Administrators](#)

1/6/22 [What You Should Know About COVID-19 Testing in Schools](#)

1/6/22 [Guidance for COVID-19 Prevention in Kindergarten \(K\)-12 Schools](#)

1/6/22 [Information about the Pfizer-BioNTech COVID-19 Vaccine](#)

1/6/22 [Schools and Childcare Programs](#)

1/5/22 [CDC Expands Booster Shot Eligibility and Strengthens Recommendations for 12-17 Year Olds](#)

.....

.....

Africa CDC [to 08 Jan 2022]

<http://www.africacdc.org/>

News

[Outbreak Brief 103: Coronavirus Disease 2019 \(COVID-19\) Pandemic](#)

4 Jan 2022

.....

.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 08 Jan 2022]

<http://en.nhc.gov.cn/>

News

[Jan 8: Daily briefing on novel coronavirus cases in China](#)

On Jan 7, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 159 new cases of confirmed infections.

[Over 7 mln vaccine doses administered in SW China's Tibet](#)

2022-01-07

National Medical Products Administration – PRC [to 08 Jan 2022]

<http://english.nmpa.gov.cn/>

News

[Over 2.87b COVID-19 vaccine doses administered on Chinese mainland](#)

2022-01-07

Over 2.87 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Jan 6.

[Chinese mainland reports 116 locally transmitted COVID-19 cases](#)

2022-01-07

The Chinese mainland on Thursday reported 116 new locally transmitted COVID-19 cases, the National Health Commission said in its daily report on Jan 7.

[CCDC Weekly Reports: Current Volume \(4\)](#)

2022-01-07 / No. 1

[View PDF of this issue](#)

:: [Outbreak Reports: A H9N2 Human Case and Surveillance of Avian Influenza Viruses in Live Poultry Markets — Huizhou City, Guangdong Province, China, 2021](#)

:: [Outbreak Reports: Three Cases Infected with Avian Influenza A\(H5N6\) Virus — Chongqing Municipality, China, January–September, 2021](#)

.....

.....

.....

Contents [click to move among sections]

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

.....

.....

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

No new digest content identified.

Paul G. Allen Frontiers Group [to 08 Jan 2022]

<https://alleninstitute.org/news-press/>

News

[New technique sorts out what different kinds of neurons do in the brain](#)

January 7, 2022

Study pinpoints a mouse neuron's role in sensing touch

BARDA – U.S. Department of HHS [to 08 Jan 2022]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 08 Jan 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 08 Jan 2022]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 08 Jan 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 08 Jan 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Informed Consent: A Monthly Review – January 2022](#)** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 08 Jan 2022]

<http://cepi.net/>

Latest News

[Reflections on 2021 from CEPI CEO Dr Richard Hatchett](#)

21 Dec 2021

By Dr. Richard Hatchett

CEPI CEO Dr Richard Hatchett offers his personal reflections on the events of the past year, and looks to the challenges ahead as the world responds to Omicron and prepares for the threat of future pandemics.

[See Perspectives above for excerpts]

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 08 Jan 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 08 Jan 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 08 Jan 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 08 Jan 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 08 Jan 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Merieux [to 08 Jan 2022]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 08 Jan 2022]

<https://www.gavi.org/>

News Releases

[COVAX awarded 2021 North-South Prize for enhancing global equitable access to COVID-19 vaccines](#)

Geneva, 21 December 2021 – The COVAX Facility has been awarded the 2021 [North-South Prize of the Council of Europe](#) in recognition of its efforts to ensure that COVID-19 vaccines are available worldwide, including in low-income countries, and for striving for a more equitable world to protect people's lives.

...The North-South Prize of the Council of Europe is awarded each year to two nominees, one from the North and one from the South, for their exceptional commitment to promoting North-South solidarity...

GHIT Fund [to 08 Jan 2022]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that

No new digest content identified.

Global Fund [to 08 Jan 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

[Global Fund Praises Norway's Leadership in Global Fight Against COVID-19](#)

22 December 2021

The Global Fund praises Norway's leadership in the global fight against COVID-19 after its decision to allocate NOK 440 million (US\$49.1 million) to the Global Fund's COVID-19 Response Mechanism (C19RM). This new contribution, which is on top of the ...

News

[Global Fund Applauds Luxembourg's Contribution to the COVID-19 Response Mechanism](#)

21 December 2021

The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds the decision by Luxembourg to contribute €2 million to the Global Fund's COVID-19 Response Mechanism.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 08 Jan 2022]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 08 Jan 2022]

<http://www.hillemanlabs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 08 Jan 2022]

<https://www.hhmi.org/news>

Press Room

Research Jan 6 2022

[Cystic Fibrosis Drugs Can Be 'Life-Changing' For Patients. New Images Reveal How These Molecules Work](#)

A mutated protein causes the genetic disease cystic fibrosis. Now, researchers have solved the structure of the protein and how certain drugs bind to it, unveiling their mode of action.

Human Vaccines Project [to 08 Jan 2022]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 08 Jan 2022]

<https://www.iavi.org/newsroom>

Latest News

FEATURES

January 5, 2022

[IAVI remembers Archbishop Desmond Tutu](#)

The archbishop advocated for the human rights of people living with HIV and tuberculosis

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 08 Jan 2022]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

[Egypt: ICRC donates protective equipment to health ministry to support fight against COVID-19](#)

The ICRC donation, worth 1 million Egyptian pounds, includes FFP2/N95 masks, protective coveralls, examination gloves, surgical gloves, body bags, and non-touch thermometers. The PPE will be sent to the health facilities in the governorates of Ismailia and North Sinai. This comes as part of the continued cooperation between the ICRC and the health ministry to support the

20-12-2021 | News release

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 08 Jan 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

[Philippines: Mounting health crisis after super typhoon](#)

06/01/2022 | *Press release*

Institut Pasteur [to 08 Jan 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release 23.12.2021

[COVID-19 – Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose](#)

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many...

IOM / International Organization for Migration [to 08 Jan 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

News 21 Dec 2021

[Global Diaspora Week: Maximizing Diaspora Contributions in Development](#)

News 21 Dec 2021

[Returning Female Migrants Face More Reintegration Challenges than Men: IOM Study](#)

ISC / International Science Council [to 08 Jan 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News

No new digest content identified.

IVAC [to 08 Jan 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 08 Jan 2022]

<http://www.ivi.int/>

IVI News & Announcements

[2021 Year in Review](#)

[Undated]

[IVI and Mozambique's INS launch mix-and-match COVID-19 vaccine study](#)

:: Study will assess the safety and immunogenicity of a heterologous regimen of two approved COVID-19 vaccines in adults

:: Aims to mitigate vaccine shortages and support flexible immunization programs

December 20, 2021

Johns Hopkins Center for Health Security [to 08 Jan 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

[Johns Hopkins Center for Health Security's COVID-19 Testing Toolkit Expands in Second Year](#)

December 21, 2021

MSF/Médecins Sans Frontières [to 08 Jan 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

South Sudan

[Hundreds of thousands of people in dire conditions months after floods](#)

Project Update 7 Jan 2022

Chad

["If the rain abandons us again, we don't know what we will do"](#)

Project Update 6 Jan 2022

Refugees, IDPs and people on the move

[MSF leaves Polish border after being blocked from assisting people](#)

Press Release 6 Jan 2022

Chad

[Tens of thousands of people flee Cameroon as violence spreads](#)

Project Update 4 Jan 2022

National Academy of Medicine - USA [to 08 Jan 2022]

<https://nam.edu/programs/>

Selected News/Programs/Events

No new digest content identified.

National Academy of Sciences - USA [to 08 Jan 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 08 Jan 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

National Vaccine Advisory Committee [NVAC] 2022 Meetings

[February 10-11, 2022](#)

NIH [to 08 Jan 2022]

<http://www.nih.gov/news-events/news-releases>

News Releases

[COVID-19 vaccination associated with a small, temporary increase in menstrual cycle length, suggests NIH-funded study](#)

January 6, 2022 — The authors noted that menstrual cycles typically vary a small amount from month to month.

[NIH celebrates FDA approval of long-acting injectable drug for HIV prevention](#)

December 21, 2021 — Approval marks pivotal expansion of HIV prevention options in the United States.

OECD [to 08 Jan 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

No new digest content identified.

PATH [to 08 Jan 2022]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 08 Jan 2022]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 08 Jan 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

6 January 2022

[New indicators added to Key Populations Atlas](#)

The UNAIDS [Key Populations Atlas](#) is an online tool that provides a range of information about members of key populations—sex workers, gay men and other men who have sex with men, people who inject drugs, transgender people and prisoners—worldwide, together with information about people living with HIV.

Information about gay men and other men who have sex with men has been expanded with the inclusion of 11 new indicators from the [EMIS](#) and [LAMIS](#) projects. Under funding from the European Commission, EMIS-2017 collected data from gay men and other men who have sex with men in 50 countries between October 2017 and January 2018. LAMIS is the Latin American version of EMIS and finished data collection across 18 additional countries in May 2018.

The 11 new indicators shown in the Key Population Atlas—on syphilis, symptomatic syphilis, gonorrhoea, symptomatic gonorrhoea, chlamydia, symptomatic chlamydia, sexually transmitted infections testing, syphilis partner notification, gonorrhoea partner notification and hepatitis A and B vaccination—were chosen because of their high relevance to the communities...

UNHCR Office of the United Nations High Commissioner for Refugees [to 08 Jan 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

[Pakistan concludes 'drive' to issue smartcards to registered Afghan refugees](#)

4 Jan 2022

UNICEF [to 08 Jan 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

12/31/2021

[Grave violations of children's rights in conflict on the rise around the world, warns UNICEF](#)

Less than half of parties to conflict globally have committed to protect children

Unitaid [to 08 Jan 2022]

<https://unitaid.org/>

Featured News

No new digest content identified.

USAID [to 08 Jan 2022]

<https://www.usaid.gov/news-information/press-releases/2021>

Selected Press Releases, Statements, Announcements

[Administrator Samantha Power's Meeting with Director of the Africa Centres for Disease Control and Prevention Dr. John Nkengasong](#)

January 4, 2022

Today, Administrator Samantha Power met with Dr. John Nkengasong, the Director of the Africa Centres for Disease Control and Prevention (Africa CDC). They discussed the recently announced whole-of-government effort, the Initiative for Global Vaccine Access (Global VAX), to accelerate global efforts to turn COVID-19 vaccines into vaccinations through expanded vaccine readiness, delivery support, and enhanced coordination. Dr. Nkengasong provided his perspective on the country capacity and political will needed to significantly ramp up vaccine access and delivery across the African continent. The Administrator and Dr. Nkengasong agreed on the importance of close collaboration between the U.S. government and the Africa CDC in achieving Global VAX goals.

[Administrator Samantha Power at the Swearing-in Ceremony for Atul Gawande, Assistant Administrator to the Bureau for Global Health](#)

January 4, 2022

In addition to his focus on strengthening health systems, Atul will lead efforts to prevent needless child and maternal deaths, respond to infectious disease threats and expand our family planning programming to better address the health and rights of women and girls. And critically, Atul will bring his characteristic mentorship and empathy to the nine offices of the Global Health Bureau as they work to spread health equity around the world.

Vaccine Equity Cooperative [nee Initiative] [to 08 Jan 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 08 Jan 2022]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 08 Jan 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 08 Jan 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[TWiV 844: Paul Offit on children, COVID, and boosters](#)

December 19, 2021

Paul Offit returns to TWiV to discuss new CDC guidance on J&J vaccine, why children should be immunized against COVID-19, and whether or not booster doses are scientifically justified.

Wellcome Trust [to 08 Jan 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 08 Jan 2022]

<https://www.wistar.org/news/press-releases>

Press Releases

Jan. 5, 2022

[Wistar and Stanford Medicine to Begin Phase 2 Clinical Trial of VK-2019 in Patients with Epstein-Barr Virus \(EBV\)-Positive Advanced Nasopharyngeal Carcinoma](#)

Phase 2 clinical trial to evaluate novel anticancer drug candidate.

WFPHA: World Federation of Public Health Associations [to 08 Jan 2022]

<https://www.wfpha.org/>

Latest News - Blog

[Public Health Leadership Coalition: A Call to Action](#)

Dec 20, 2021

Global challenges can only be overcome through global efforts and the adoption of appropriate global approaches to address health threats at the animal, human, and environmental interfaces.

Global public health leaders, working within the framework of the World Federation of Public Health Associations, have called for actions to promote equity, public health leadership and global coordination to address pressing global health challenges, including the COVID-19 pandemic and other health threats.

World Bank [to 08 Jan 2022]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

World Bank Prices First CAD Sustainable Development Bond of 2022 and Highlights Health and COVID-19 Response Efforts

WASHINGTON, D.C., January 6, 2022 – The World Bank (International Bank for Reconstruction and Development, IBRD, Aaa/AAA) today priced a new 5-year CAD 1.5 billion benchmark that matures on January 19...

Date: January 06, 2022 Type: Press Release

World Bank Supports Burundi's Response to COVID-19

WASHINGTON, December 22, 2021 - The World Bank Group approved today US\$60 million in additional funding for the COVID-19 Preparedness and Response Project in Burundi to help the Government prevent, detect...

Date: December 22, 2021 Type: Press Release

World Bank's Operational Response to COVID-19 (Coronavirus) in East Asia and the Pacific

The World Bank Group is taking broad, fast action to help developing countries strengthen their pandemic response, increase disease surveillance, improve public health interventions, and help the private...

Date: December 22, 2021 Type: Brief

Joint Statement of the Multilateral Leaders Taskforce on Scaling Covid-19 Tools, December 17, 2021: "From Vaccines to Vaccinations"

Washington, December 22, 2021 — The heads of the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization held high-level consultations with...

Date: December 22, 2021 Type: Statement

[See Perspectives above for detail]

World Organisation for Animal Health (OIE) [to 08 Jan 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 08 Jan 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

International organizations discuss how to improve access to COVID vaccines, countermeasures

22 December 2021

The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization held on 17 December high-level consultations with UNICEF and Gavi aimed at increasing access to COVID-19-related vaccines and other critical medical countermeasures in low—and lower-middle-income countries. The four agency heads — Kristalina Georgieva (IMF), David Malpass (World Bank), Dr Tedros Adhanom Ghebreyesus (WHO) and Dr Ngozi Okonjo-Iweala (WTO) — issued a joint statement on behalf of the Multilateral Leaders Task Force.

[See Perspectives above for detail]

.....

ARM [Alliance for Regenerative Medicine] [to 08 Jan 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 08 Jan 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 08 Jan 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 08 Jan 2022]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 08 Jan 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 08 Jan 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 08 Jan 2022]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

* * * *

Contents [click to move among sections]

::

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 12: E905-1005 Dec 2021

<https://journalofethics.ama-assn.org/issue/health-justice-and-diversity-medical-school-admissions>

Health Justice and Diversity in Medical School Admissions

The Association of American Medical Colleges defines members of populations underrepresented in medicine "relative to their numbers in the general population." Diversity motivates key clinical and professional educational goals that can be sources of common ground when conflict emerges about which kinds of diversity should matter most and how applicants' memberships in minoritized groups should be regarded in admissions processes. Diversification and inclusion strategies vary in how effectively they motivate equity or retention among members of different groups in medicine, so how influential they should be is hotly contested and worthy of ethical investigation.

[No digest content identified]

American Journal of Infection Control

January 2022 Volume 50 Issue 1 p1-122

<http://www.ajicjournal.org/current>

Major Articles

[Estimating pediatric cases of COVID-19 over time in the United States: Filling in a gap in public use data](#)

Timothy L Wiemken, Samson L Niemotka, Jacob A Clarke, Christopher G Prener, Ana Santos Rutschman

Published online: October 27, 2021

[Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study](#)

Renuka Ananth Kalyan Kadali, Ravali Janagama, Siva H. Yedlapati, ...Hanumantha R. Jogu, Shailaja Racherla, Isha Shah

Published online: October 27, 2021

p8-14

Open Access

[The safety profile of COVID-19 vaccinations in the United States](#)

Amninder Singh, Ratesh Khillan, Yogendra Mishra, Sumit Khurana

Published online: October 23, 2021

p15-19

[COVID-19 vaccination hesitancy among health care workers, communication, and policy-making](#)

Stephanie M. Toth-Manikowski, Eric S. Swirsky, Rupali Gandhi, Gina Piscitello

Published online: October 12, 2021

p20-25

American Journal of Preventive Medicine

February 2022 Volume 62 Issue 2 p149-306

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

January 2022 112(1)

<http://ajph.aphapublications.org/toc/ajph/current>

NOTES FROM THE FIELD

[Deployment of Health Equity Strike Teams to Address COVID-19 Vaccine Disparities in Arkansas, 2021](#)

Health Service Delivery, Immunization/Vaccines, Access to Care

Austin Porter, Samantha Wells, Chimfunanya Smith, Namvar Zohoori, George Pro and Michelle R. Smith

112(1), pp. 29–33

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 6 (Dec 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/6/tpmd.105.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

December 2021 Volume 174, Issue 12

<http://annals.org/aim/issue>

Original Research

[Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020](#)

FREE

Meredith S. Shiels, PhD, MHS, Anika T. Haque, MPH, Emily A. Haozous, PhD, RN, Paul S. Albert, PhD,
Pages:1693–1699

[Measuring the COVID-19 Mortality Burden in the United States - A Microsimulation Study](#)

FREE

Julian Reif, PhD, Hanke Heun-Johnson, PhD, Bryan Tysinger, PhD, Darius Lakdawalla, PhD
Pages:1700–1709

Medicine and Public Issues

[Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action](#)

Elizabeth J. Ragan, MPH, Caitryn McCallum, MPH, Jai Marathe, MD, Manisha Cole, MS, [... et al.](#)
Pages:1727–1732

Special Articles

[COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology](#)

FREE

Christine Laine, MD, MPH, Deborah Cotton, MD, MPH, Darilyn V. Moyer, MD
Pages:1733–1734

Artificial Intelligence – An International Journal

Volume 302 January 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 08 Jan 2022)

[No new digest content identified]

BMJ Global Health

January 2022 - Volume 7 - 1

<https://gh.bmj.com/content/7/1>

Original research

[Ethical health security in the age of antimicrobial resistance](#) (7 January, 2022)

Kari Pahlman, Anson Fehross, Greg J Fox, Diego S Silva

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 08 Jan 2022)

[Two decades of regional trends in vaccination completion and coverage among children aged 12-23 months: an analysis of the Uganda Demographic Health Survey data from 1995 to 2016](#)

Childhood vaccination is an important public health intervention but there is limited information on coverage, trends, and determinants of vaccination completion in Uganda at the regional level. We examined tr...

Authors: Gerald Okello, Jonathan Izudi, Immaculate Ampeire, Frehd Nghania, Carine Dochez and Niel Hens

Citation: BMC Health Services Research 2022 22:40

Content type: Research

Published on: 7 January 2022

[Economic impact of switching from partially combined vaccine "Pentaxim® and hepatitis B" to fully combined vaccine "Hexaxim®" in the Malaysian National Immunization Program](#)

The decision to implement new vaccines should be supported by public health and economic evaluations. Therefore, this study was primarily designed to evaluate the economic impact of switching from partially co...

Authors: Syed Mohamed Aljunid, Lama Al Bashir, Aniza Binti Ismail, Azimatun Noor Aizuddin, S. A. Zafirah Abdul Rashid and Amrizal Muhammad Nur

Citation: BMC Health Services Research 2022 22:34

Content type: Research

Published on: 5 January 2022

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 08 Jan 2022)

[Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey](#)

Vaccination efforts to eradicate polio currently focus on children under 5 years of age, among whom most cases of poliomyelitis still occur. However, in the Democratic Republic of the Congo (DRC), an outbreak ...

Authors: Vivian H. Alfonso, Arie Voorman, Nicole A. Hoff, William C. Weldon, Sue Gerber, Adva Gadoth, Megan Halbrook, Amelia Goldsmith, Patrick Mukadi, Reena H. Doshi, Guillaume Ngoie-Mwamba, Trevon L. Fuller, Emile Okitolonda-Wemakoy, Jean-Jacques Muyembe-Tamfum and Anne W. Rimoin

Citation: BMC Infectious Diseases 2022 22:30

Content type: Research

Published on: 5 January 2022

[Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease](#)

Patients with Inflammatory Bowel Disease (IBD) are at increased risk of serious infections, including vaccine preventable diseases. Current evidence suggests uptake of additional recommended special risk vacci...

Authors: Timothy Ford, Margie Danchin, Alissa McMinn, Kirsten Perrett, George Alex and Nigel W. Crawford

Citation: BMC Infectious Diseases 2022 22:6

Content type: Research

Published on: 4 January 2022

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 08 Jan 2022)

[A systematic approach to the disclosure of genomic findings in clinical practice and research: a proposed framework with colored matrix and decision-making pathways](#)

Whether and how to disclose genomic findings obtained in the course of genomic clinical practice and medical research has been a controversial global bioethical issue over the past two decades. Although severa...

Authors: Kenji Matsui, Keiichiro Yamamoto, Shimon Tashiro and Tomohide Ibuki

Citation: BMC Medical Ethics 2021 22:168

Content type: Research

Published on: 25 December 2021

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 08 Jan 2022)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 08 Jan 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublikealth.biomedcentral.com/articles>

(Accessed 08 Jan 2022)

[Predicting human papillomavirus vaccine uptake in men who have sex with men the influence of vaccine price and receiving an HPV diagnosis](#)

To understand how human papillomavirus (HPV) screening results, HPV-related knowledge and attitudes are related to vaccination intention in three cost ranges and the actual vaccination behavior in a community ...

Authors: Po-Yi Yao, Chung-Ying Lin, Nai-Ying Ko, Huachun Zou, Chia-Wen Lee and Carol Strong

Citation: BMC Public Health 2022 22:28

Content type: Research article

Published on: 6 January 2022

Medicines and vaccines supply chains challenges in Nigeria: a scoping review

Medicines and vaccines supply chains represent critical systems for realising one of the major targets of the United Nations' third Sustainable Development Goals (SDGs)—access to safe, effective, quality, and

Authors: Victory O. Oluotase, Chinwe J. Iwu-Jaja, Cynthia P. Akuoko, Emmanuel O. Adewuyi and Vishnu Khanal

Citation: BMC Public Health 2022 22:11

Content type: Research

Published on: 5 January 2022

Comparison of hesitancy between COVID-19 and seasonal influenza vaccinations within the general Hungarian population: a cross-sectional study

The willingness to get COVID-19 or seasonal influenza vaccines has not yet been thoroughly investigated together, thus, this study aims to explore this notion within the general adult population.

Authors: Viktor Dombrádi, Tamás Joó, Gergely Palla, Péter Pollner and Éva Belicza

Citation: BMC Public Health 2021 21:2317

Content type: Research

Published on: 23 December 2021

Economic burden of varicella in Europe in the absence of universal varicella vaccination

Though the disease burden of varicella in Europe has been reported previously, the economic burden is still unknown. This study estimated the economic burden of varicella in Europe in the absence of Universal ...

Authors: Manjiri Pawaskar, Estelle Méroc, Salome Samant, Elmira Flem, Goran Bencina, Margarita Riera-Montes and Ulrich Heininger

Citation: BMC Public Health 2021 21:2312

Content type: Research

Published on: 21 December 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 08 Jan 2022)

The geography of COVID-19 misinformation: using geospatial maps for targeted messaging to combat misinformation on COVID-19, South Africa

The proliferation of false information on COVID-19 mostly through social media is adversely affecting control efforts. The objective of this study was to identify areas where targeted effective messaging can b...

Authors: Lucy Chimoyi, Tonderai Mabuto, Tanyaradzwa Dube, Nasiphi Ntombela, Tshegang Nchachi, Dakalo Tshisebe, Candice M. Chetty-Makkan and Geoffrey K. Setswe

Citation: BMC Research Notes 2021 14:468

Content type: Research note

Published on: 24 December 2021

BMJ Evidence-Based Medicine

December 2021 - Volume 26 - 6

<https://ebm.bmj.com/content/26/6>

[Reviewed earlier]

BMJ Open

December 2021 - Volume 11 - 12

<https://bmjopen.bmj.com/content/11/12>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(12); 2021 Dec 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/394921/>

[Reviewed earlier]

Cell

Jan 06, 2022 Volume 185 Issue 1 p1-220

<https://www.cell.com/cell/current>

Commentary

[BRAIN 2.0: Transforming neuroscience](#)

John Ngai

The NIH BRAIN Initiative is entering a new phase. Three large new projects—a comprehensive human brain cell atlas, a whole mammalian brain microconnectivity map, and tools for precision access to brain cell types—promise to transform neuroscience research and the treatment of human brain disorders.

Child Care, Health and Development

Volume 48, Issue 1 Pages: 1-175 January 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 111, Issue 1 Pages: 1-331 January 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Real World Evidence

Editorial

Free Access

[The “Coming of Age” of Real-World Evidence in Drug Development and Regulation](#)

[Peter K Honig](#)

Pages: 11-14

First Published:16 December 2021

Perspective

Open Access

[Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value](#)

[Peter Arlett](#), [Jesper Kjær](#), [Karl Broich](#), [Emer Cooke](#)

Pages: 21-23

First Published:19 November 2021

Open Access

[Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World](#)

Douglas McNair, Murray Lumpkin, Steven Kern, Daniel Hartman

Pages: 44-51

First Published:16 October 2021

Open Access

[Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design](#)

Simon Dagenais, Leo Russo, Ann Madsen, Jen Webster, Lauren Becnel

Pages: 77-89

First Published:28 November 2021

Clinical Therapeutics

December 2021 Volume 43 Issue 12 p2041-2172

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 6, December 2021

<https://journals.sagepub.com/toc/ctja/18/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 08 Jan 2022]

[Measles in conflict-affected northern Syria: results from an ongoing outbreak surveillance program](#)

The Syrian conflict has dramatically changed the public health landscape of Syria since its onset in March of 2011. Depleted resources, fractured health systems, and increased security risks have disrupted man...

Authors: Sammy Mehtar, Naser AlMhawish, Kasim Shobak, Art Reingold, Debarati Guha-Sapir and Rohini J. Haar

Citation: Conflict and Health 2021 15:95

Content type: Research

Published on: 21 December 2021

Contemporary Clinical Trials

Volume 112 January 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/112/suppl/C>

Research article Open access

[Implementation of platform trials in the COVID-19 pandemic: A rapid review](#)

Alyssa M. Vanderbeek, Judith M. Bliss, Zhulin Yin, Christina Yap

Article 106625

The CRISPR Journal

Volume 4, Issue 6 / December 2021

<https://www.liebertpub.com/toc/crispr/4/6>

[New issue; No digest content identified]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2022 - Volume 35 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

HIV INFECTIONS AND AIDS

Edited by David Dockrell

[What will it take to meet UNAIDS targets for preexposure prophylaxis users?](#)

Sullivan, Patrick Sean; Siegler, Aaron Julius

Current Opinion in Infectious Diseases. 35(1):1-8, February 2022.

[Immunotherapeutic approaches to HIV cure and remission](#)

Lee, Ming J.; Fidler, S.; Frater, John

Current Opinion in Infectious Diseases. 35(1):31-41, February 2022.

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 8, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 46, Issue 1 Pages: 1-298 January 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 23 Issue 1 5 January 2022

<https://www.embopress.org/toc/14693178/current>

Science & Society 24 November 2021

[**The Physalis Improvement Project: blending research with community science: How community science can advance research**](#)

[Joyce Van Eck](#)

The Physalis community science project shows how citizen science not just communicates with and engages people in research but also how it can inform and benefit the professional scientists.

Science & Society 13 December 2021 Free to Read

[**An ongoing science-society-ethics experiment: The human challenge trial debate in COVID-19 pandemic**](#)

[Sonia M R Vasconcelos, et al.](#)

Human challenge trials to deliberately infect volunteers with SARS-CoV-2 should inspire wider debates about research ethics and participants' motivations to take part in such studies.

Emerging Infectious Diseases

Volume 28, Number 1—January 2022

<http://wwwnc.cdc.gov/eid/>

Synopses

[**Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States \[PDF - 1.82 MB - 9 pages\]**](#)

[R. Gharpure et al.](#)

Research

[**Risk Factors for SARS-CoV-2 Infection Among US Healthcare Personnel, May–December 2020 \[PDF - 2.35 MB - 9 pages\]**](#)

[N. Chea et al.](#)

Epidemics

Volume 37 December 2021

<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 6 Pages: 1-48 November–December 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupač on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 19 December 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/19/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue 6, December 2021

<https://academic.oup.com/eurpub/issue/31/6>

Vaccination

[Differences between influenza and pertussis vaccination uptake in pregnancy: a multi-center survey study in Italy](#)

Luz Maria Vilca, Laura Sarno, Elena Cesari, Annalisa Vidiri, Patrizio Antonazzo ...

European Journal of Public Health, Volume 31, Issue 6, December 2021, Pages 1150–1157,

<https://doi.org/10.1093/eurpub/ckab095>

[‘I’m not an anti-vaxer!’—vaccine hesitancy among physicians: a qualitative study](#)

Franziska Ecker, Ruth Kutalek

European Journal of Public Health, Volume 31, Issue 6, December 2021, Pages 1157–1163,
<https://doi.org/10.1093/eurpub/ckab174>

Expert Review of Vaccines

Vol 20 (12) 2021

<https://www.tandfonline.com/toc/ierv20/current>

Review

[A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects](#)

Philippe Buchy, Jing Chen, Xu-Hao Zhang, Bernd Benninghoff, Christa Lee & Gyneth Lourdes Bibera
Pages: 1499-1514

Published online: 20 Apr 2021

[DNA vaccines for SARS-CoV-2: toward third-generation vaccination era](#)

Vivek P Chavda, Radhika Pandya & Vasso Apostolopoulos

Pages: 1549-1560

Published online: 28 Oct 2021

[Vaccinomics: a future avenue for vaccine development against emerging pathogens](#)

José de la Fuente & Marinela Contreras

Pages: 1561-1569

Published online: 13 Oct 2021

[COVID-19 vaccination in pregnant and lactating women: a systematic review](#)

Raffaele Falsaperla, Guido Leone, Maria Familiari & Martino Ruggieri

Pages: 1619-1628

Published online: 11 Oct 2021

Article

[Effects of the COVID-19 pandemic on routine pediatric vaccination in Brazil](#)

Victor Santana Santos, Sarah Cristina Fontes Vieira, Ikaro Daniel de Carvalho Barreto, Vanessa Tavares de Gois-Santos, Ariel Oliveira Celestino, Carla Domingues, Luis Eduardo Cuevas & Ricardo Queiroz Gurgel

Pages: 1661-1666

Published online: 21 Oct 2021

Forum for Development Studies

Volume 48, 2021 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 08 Jan 2022]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 4 December 31, 2021

<http://www.ghspjournal.org/content/current>

EDITORIALS

Open Access

[A Call to Action: Reinvigorating Interest and Investments in Health Infrastructure](#)

Lindsay M. Mallick and Joshua Amo-Adjei

Global Health: Science and Practice December 2021, 9(4):711-715; <https://doi.org/10.9745/GHSP-D-21-00674>

Infrastructure investments can contribute substantially to alleviating burdens of morbidity and mortality while also providing a positive return on investment in the long term.

COMMENTARIES

[COVID-19 Partners Platform—Accelerating Response by Coordinating Plans, Needs, and Contributions During Public Health Emergencies: COVID-19 Vaccines Use Case](#)

Angela K. Shen, M. Anne Yu, Ann Lindstrand, Sanjiv M. Baxi, Océane Jousset, Katherine O'Brien and Lucy Boulanger

Global Health: Science and Practice December 2021, 9(4):725-732; <https://doi.org/10.9745/GHSP-D-21-00460>

The World Health Organization COVID-19 Partners Platform represents the first step towards a new model of health crisis information sharing across stakeholders and could evolve into an engagement mechanism of choice for future cross-border public health emergencies.

VIEWPOINTS

Open Access

[Equitable Open Access Publishing: Changing the Financial Power Dynamics in Academia](#)

Dominique Vervoort, Xiya Ma and Hloni Bookholane

Global Health: Science and Practice December 2021, 9(4):733-736; <https://doi.org/10.9745/GHSP-D-21-00145>

The growth in open access publishing in academia benefits readership but disproportionately hinders unfunded or lesser-funded researchers. Few journals create comprehensive means to bridge these inequities, calling for a shift in academic publishing practices.

Reviews

[Lessons Learned During the COVID-19 Pandemic to Strengthen TB Infection Control: A Rapid Review](#)

Helena J. Chapman and Bienvenido A. Veras-Estévez

Global Health: Science and Practice December 2021, 9(4):964-977; <https://doi.org/10.9745/GHSP-D-21-00368>

In light of competing health priorities of COVID-19 and TB, we propose recommendations to strengthen health system preparedness for optimal TB control across low- and middle-income countries during and after the COVID-19 pandemic.

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 08 Jan 2022]

[No new digest content identified]

Global Public Health

Volume 17, Issue 1 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

[New issue; No digest content identified]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 08 Jan 2022]

[COVID-19 data are messy: analytic methods for rigorous impact analyses with imperfect data](#)

Authors: Michael A. Stoto, Abbey Woolverton, John Kraemer, Pepita Barlow and Michael Clarke

Content type: Commentary

6 January 2022

Health and Human Rights

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 10, December 2021

<https://academic.oup.com/heapol/issue/36/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 08 Jan 2022]

[Reviewed earlier]

Human Gene Therapy

Volume 32, Issue 23-24 / December 2021

<https://www.liebertpub.com/toc/hum/32/23-24>

Perspectives

[The French Society for Cell and Gene Therapy: Our Objectives and Partnerships](#)

Els Verhoeyen and Olivier Nègre

Pages:1423–1424

Published Online:16 December 2021

<https://doi.org/10.1089/hum.2021.29185.eve>

[Spanish Society of Gene and Cell Therapy](#)

Gloria González Asequinolaza, Ander Izeta, and Francisco Martin Molina

Pages:1425–1426

Published Online:17 December 2021

<https://doi.org/10.1089/hum.2021.29190.gga>

Clinical Developments Free

[Institutional Framework for the Management of Human Genetic Resources in China](#)

Wei Li and Jiajv Chen

Pages:1495–1500

Published Online:26 August 2021

<https://doi.org/10.1089/hum.2021.096>

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

[Localisation and local humanitarian action](#)

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021
<https://www.tandfonline.com/toc/khvi20/current>
[Reviewed earlier]

Immunity

Dec 14, 2021 Volume 54 Issue 12 p2671-2922
<https://www.cell.com/immunity/current>
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 08 Jan 2022]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>
[Accessed 08 Jan 2022]

[The COVID-19 vaccination campaign in Bhutan: strategy and enablers](#)

Bhutan has reported a total of 2596 COVID-19 cases and three deaths as of September 15, 2021. With support from India, the United States, Denmark, the People's Republic of China, Croatia and other countries, B...

Authors: Tsheten Tsheten, Phurpa Tenzin, Archie C. A. Clements, Darren J. Gray, Lhawang Ugyel and Kinley Wangdi

Citation: Infectious Diseases of Poverty 2022 11:6

Content type: Opinion

Published on: 5 January 2022

[The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China](#)

Reaching optimal vaccination rates is an essential public health strategy to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to simulate the optimal vaccination strategy to control t...

Authors: Ze-yu Zhao, Yan Niu, Li Luo, Qing-qing Hu, Tian-long Yang, Mei-jie Chu, Qiu-ping Chen, Zhao Lei, Jia Rui, Cheng-long Song, Sheng-nan Lin, Yao Wang, Jing-wen Xu, Yuan-zhao Zhu, Xing-chun Liu, Meng Yang...

Citation: Infectious Diseases of Poverty 2021 10:140

Content type: Research Article

Published on: 28 December 2021

[Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial](#)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomi...

Authors: Yongliang Feng, Jing Chen, Tian Yao, Yue Chang, Xiaoqing Li, Rongqin Xing, Hong Li, Ruixue Xie, Xiaohong Zhang, Zhiyun Wei, Shengcai Mu, Ling Liu, Lizhong Feng and Suping Wang
Citation: Infectious Diseases of Poverty 2021 10:138
Content type: Research Article
Published on: 22 December 2021

International Health

Volume 13, Issue 6, November 2021
<https://academic.oup.com/inthealth/issue/13/6>
[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)
<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>
[New issue; No digest content identified]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022
<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>
Original Research Articles

[Utility of pneumococcal vaccine among elderly population in buraidah primary health care centers](#)

Sulaiman A. Alawaji, Chandra S. Kalevaru
DOI: [10.18203/2394-6040.ijcmph20214980](https://doi.org/10.18203/2394-6040.ijcmph20214980)

[Impact of electronic vaccine intelligence network application used in immunization sessions in Pune city](#)

Damini S. Mahanubhav, Nandkumar M. Salunke, Sangita C. Shelke, Malangori A. Parande, Muralidhar P. Tambe
DOI: [10.18203/2394-6040.ijcmph20214857](https://doi.org/10.18203/2394-6040.ijcmph20214857)

[Awareness on COVID 19 vaccination among public: a questionnaire surveys](#)

Prabhu Subramani, Jisa James, Kritika Saikia, Akash D., Albert Jack Mathew B., Aishwarya S.
DOI: [10.18203/2394-6040.ijcmph20215012](https://doi.org/10.18203/2394-6040.ijcmph20215012)

International Journal of Epidemiology

Volume 50, Issue 6, December 2021
<https://academic.oup.com/ije/issue>
Opinion

[Public health science in the public square: lobby, litigate, listen](#)

Henry Greenberg, Charles C Branas
International Journal of Epidemiology, Volume 50, Issue 6, December 2021, Pages 1765–1767,
<https://doi.org/10.1093/ije/dyab136>

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

January 2022 Volume 114 p1-278

<https://www.ijidonline.com/current>

Editorial

[Emergence of new SARS-CoV-2 Variant of Concern Omicron \(B.1.1.529\) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts](#)

Eskild Petersen, Francine Ntoumi, David S Hui,...Richard Kock, Giuseppe Ippolito, Alimuddin Zumla

Published online: December 01, 2021

Coronavirus (COVID-19) Collection

[COVID-19 vaccine acceptance in South Asia: a multi-country study](#)

Mohammad Delwer Hossain Hawlader, Mohammad Lutfor Rahman, Anum Nazir, ... Shailesh Kumar Pandit, Sujata Giri, Mohammad Hayatun Nabi

Published online: September 28, 2021

[SARS-CoV-2 infection in fully vaccinated healthcare workers](#)

Miriam Hernández Porto, Beatriz Castro, Zaida Diaz, Yanet Pedroso, María José Ramos, María Lecuona

Published online: June 09, 2021

p183-184

[Country differences in transmissibility, age distribution and case-fatality of SARS-CoV-2: a global ecological analysis](#)

Caroline Favas, Prudence Jarrett, Ruwan Ratnayake, Oliver J Watson, Francesco Checchi

Published online: November 05, 2021

p210-218

JAMA

January 4, 2022, Vol 327, No. 1, Pages 11-93

<https://jamanetwork.com/journals/jama/currentissue>

Medical News & Perspectives

[Why Parents Still Hesitate to Vaccinate Their Children Against COVID-19](#)

Melissa Suran, PhD, MSJ

free access has audio

JAMA. 2022;327(1):23-25. doi:10.1001/jama.2021.21625

This Medical News feature discusses concerns about giving children the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine despite federal recommendations.

[See capture of online first JAMA series on COVID in Perspectives above]

JAMA Network

[COVID-19 Update January 8, 2022](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

January 2022, Vol 176, No. 1, Pages 7-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Viewpoint

[COVID-19 Vaccination for Caregivers in the Pediatric Medical Home A Call to Action to Improve Community Vaccination Rates](#)

Andrea Milne Wenderlich, MD, MS; Cynthia Rand, MD, MPH; Jill Halterman, MD, MPH

free access

JAMA Pediatr. 2022;176(1):16-17. doi:10.1001/jamapediatrics.2021.4214

This Viewpoint discusses providing COVID-19 vaccine education and offering vaccines to pediatric patients and their caregivers at scheduled wellness visits.

Editorial

[If Young Children's Risk of SARS-CoV-2 Infection Is Similar to That of Adults, Can Children Also Contribute to Household Transmission?](#)

Flor M. Munoz, MD

free access

JAMA Pediatr. 2022;176(1):19-21. doi:10.1001/jamapediatrics.2021.4225

[COVID-19 and Routine Childhood Vaccinations—Identifying Gaps and Informing Solutions](#)

Brian P. Jansen, MD, MSHP; Alexander G. Fiks, MD, MSCE

free access

JAMA Pediatr. 2022;176(1):21-23. doi:10.1001/jamapediatrics.2021.4248

Original Investigation

[Association of the COVID-19 Pandemic With Routine Childhood Vaccination Rates and Proportion Up to Date With Vaccinations Across 8 US Health Systems in the Vaccine Safety Datalink](#)

Malini B. DeSilva, MD, MPH; Jacob Haapala, MPH; Gabriela Vazquez-Benitez, PhD; et al.

free access

JAMA Pediatr. 2022;176(1):68-77. doi:10.1001/jamapediatrics.2021.4251

This surveillance study examines the rate of vaccination and proportion of individuals up to date with vaccines in a cohort of 2.8 million children aged 0 to 18 years across 8 US health systems.

JBI Evidence Synthesis

December 2021 - Volume 19 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

January 2022 Volume 70 Issue 1 p1-170

<https://www.jahonline.org/current>
[New issue; No digest content identified]

Journal of Artificial Intelligence Research

Vol. 73 (2022)
<https://www.jair.org/index.php/jair>
[New issue; No digest content identified]

Journal of Community Health

Volume 46, issue 6, December 2021
<https://link.springer.com/journal/10900/volumes-and-issues/46-6>
[Reviewed earlier]

Journal of Development Economics

Volume 154 January 2022
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/154/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022
<http://journals.sagepub.com/toc/jre/current>
Empirical Studies on Ethical Issues in Research with Specific Populations
[Human Research Ethics Committee Experiences and Views About Children's Participation in Research: Results From the MESSI Study](#)
[Stephanie Taplin](#), [Jenny Chalmers](#), [Judith Brown](#), [Tim Moore](#), [Anne Graham](#), [Morag McArthur](#)
First Published October 12, 2021; pp. 70–83

[A Survey to Determine the Capacity Development Needs of Research Ethics Committee Administrators in South Africa](#)

[Mutshidzi A. Mulondo](#), [Joyce M. Tsoka-Gwegweni](#), [Puleng LenkaBula](#), [Perpetual Chikobvu](#)
First Published November 22, 2021; pp. 84–93

[Assessment of the Operational Characteristics of Research Ethics Committees in Ghana](#)

[Samuel Asiedu Owusu](#), [Grace Addison](#), [Barbara Redman](#), [Lisa Kearns](#), [Paul Amuna](#), [Amos Laar](#)
First Published October 19, 2021; pp. 114–128

Journal of Epidemiology & Community Health

December 2021 - Volume 75 - 12
<https://jech.bmj.com/content/75/12>
[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 4 Pages: 257-345 December 2021
<https://onlinelibrary.wiley.com/toc/17565391/current>
[New issue; No digest content identified]

Journal of Global Ethics

Volume 17, Issue 2, 2021
<http://www.tandfonline.com/toc/rjge20/current>
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 4, November 2021
<https://muse.jhu.edu/issue/46802>
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 6, December 2021
<https://link.springer.com/journal/10903/volumes-and-issues/23-6>
[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 4
<https://www.tandfonline.com/toc/wimm20/current>
[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021
<https://academic.oup.com/jid/issue/224/6>
[Reviewed earlier]

Journal of Medical Ethics

January 2022 - Volume 48 - 1
<http://jme.bmj.com/content/current>
[New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 4 (2021)
<https://digitalrepository.aurorahealthcare.org/jpcrr/>
Cancer Screening
[Reviewed earlier]

Journal of Pediatrics

January 2022 Volume 240 p1-324

<http://www.jpeds.com/current>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 08 Jan 2022]

[Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research](#)

While having access to safe and efficient vaccines is essential for eradicating the COVID-19 pandemic, gaining marketing authorisation is a critical step in enabling and speeding this process. On December 2, 2...

Authors: Nasir Abbas and Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2021 14:110

Content type: Commentary

Published on: 24 December 2021

Journal of Public Health Management & Practice

January/February 2022 - Volume 28 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

Commentaries

[Vaccine Liability in COVID-19](#)

Rosenblum, Andrew J.

Journal of Public Health Management and Practice. 28(1):3-5, January/February 2022.

Research Reports

[Willingness to Get a COVID-19 Vaccine and Reasons for Hesitancy Among Medicare Beneficiaries: Results From a National Survey](#)

Luo, Huabin; Qu, Haiyan; Basu, Rashmita; More

Journal of Public Health Management and Practice. 28(1):70-76, January/February 2022.

[Using Public Deliberation to Set Priorities: The Case of COVID-19 Vaccine Access in New York City](#)

Scherer, Maya; Kamler, Alexandra; Weiss, Linda; More

Journal of Public Health Management and Practice. 28(1):86-94, January/February 2022.

Journal of Public Health Policy

Volume 42, issue 4, December 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-4>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

December 2021 Volume 18 Issue 185

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 8, December 2021

<https://academic.oup.com/jtm/issue>

Editorial

Dengue during the COVID-19 pandemic

Annelies Wilder-Smith, MD

Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab183,

<https://doi.org/10.1093/jtm/taab183>

Despite coronavirus disease 2019-related disruptions in controlling dengue, efforts need to be maintained to prevent vector-borne diseases during this pandemic. Although travel restrictions brought a global halt to mobility and therefore also a substantial decline of imported and travel-associated dengue, dengue will become dominant again in travel medicine as soon as international travel resumes.

No further delays in offering booster doses in countries experiencing a major resurgence of COVID-19

Benjamin Davido, MD, MSc, Guillaume Davido, MD, MSc, Djillali Annane, MD, PhD

Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab187,

<https://doi.org/10.1093/jtm/taab187>

Covid booster shots should be proposed and recommended to all fully vaccinated individuals, considering antibody levels are waning over time and that the risk of being infected typically reappears after 6 months.

Original Articles

Editor's Choice

Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study

Neuberger Ami, MD, Nadir Eyal, MD, Biber Asaf, MD, Avni Chen, MD, Brom Adi, MD ...

Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab071,

<https://doi.org/10.1093/jtm/taab071>

Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study

Luisa Carnino, MD, Pauline Vetter, MD, Nicolas Peyraud, MD, Sigiriya Aebischer-Perone, MD, François Chappuis, MD, PhD ...

Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab086,

<https://doi.org/10.1093/jtm/taab086>

[Global burden for dengue and the evolving pattern in the past 30 years](#)

Xiaorong Yang, PhD, Mikkel B M Quam, PhD, Tongchao Zhang, PhD, Shaowei Sang, PhD
Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab146,
<https://doi.org/10.1093/jtm/taab146>

[Conducting mass gathering events during the COVID-19 pandemic: a case study of Kumbh Mela 2021 as a potential 'super spreader event'](#)

Saurabh Shukla, PhD, Ramsha Khan, M Tech, Yusuf Ahmed, BM, MPH, FRCOG, Ziad A Memish, MD, FRCPC, FACP, FFPH
Journal of Travel Medicine, Volume 28, Issue 8, December 2021, taab160,
<https://doi.org/10.1093/jtm/taab160>

Journal of Virology

Volume 95 Number 24 November 2021
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Jan 08, 2022 Volume 399 Number 1032 0p117-210, e1
<https://www.thelancet.com/journals/lancet/issue/current>
Editorial

[Children and adolescents deserve a better future](#)

The Lancet

In January, 2020, we announced a Lancet campaign on child and adolescent health. Our intention was to refocus on child mortality, and on the recognition that adolescents matter in global health, at a time when progress had stalled or in some cases reversed amid changing political and environmental circumstances. Little did we know then what the next 2 years would bring.

COVID-19 has been—and still is—a catastrophe for children and young people. In a December report, UNICEF called the pandemic “the biggest threat to children in our 75-year history”. Widespread school and university closures mean that there is now an unprecedented educational and skills deficit globally, with inequities widening and disadvantaged children and adolescents falling even further behind. Digital learning works only for those who have supportive home environments, internet access, and teachers capable of effective online teaching. According to UNICEF, two-thirds of children and young people do not have an internet connection at home...

...National policy makers and the international community have dismally failed to protect children and adolescents during the COVID-19 pandemic. With the new wave of infections with the omicron (B.1.1.529) variant, further school closures are happening again. Vaccination of children is slow at best, with confusing messages and bewildering national differences in recommendations. Clearly, decisions made for our children and young people without their say have been detrimental. Yet, out of such catastrophic times, real transformative change might emerge. Young people want a different world. They want not only to be heard in advocacy roles or have a seat at the table, they want to take part in decision making and policy development. Children in All Policies 2030 (CAP-2030), which aims to put the health and wellbeing of children and adolescents at the centre of sustainable development

following the recommendations of a 2020 WHO–UNICEF–Lancet Commission, is helping to give a voice to young people. But a global shift towards true involvement needs much more...

Comment

[The value of vaccine programme impact monitoring during the COVID-19 pandemic](#)

Justin R Ortiz, Kathleen M Neuzil

Articles

[Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data](#)

Lucy A McNamara, et al.

The Lancet Child & Adolescent Health

Jan 2022 Volume 6 Number 1 p1-70, e1-e4

<https://www.thelancet.com/journals/lanchi/issue/current>

Comment

[Human papillomavirus vaccination for young survivors of cancer](#)

Noel T Brewer, Qian Huang, Benjamin Z Kahn Articles

Articles

[Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial](#)

Wendy Landier, et al

Young survivors of cancer are at increased risk for cancers that are related to human papillomavirus (HPV), primarily caused by oncogenic HPV types 16 and 18. We aimed to examine the immunogenicity and safety of the three-dose series of HPV vaccine in young survivors of cancer.

Lancet Digital Health

Jan 2022 Volume 4 Number 1 e1-e74

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

Lancet Global Health

Jan 2022 Volume 10 Number 1 e1-e153

<https://www.thelancet.com/journals/langlo/issue/current>

Viewpoint

[Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines](#)

Miquel Oliu-Barton, et al.

[A diagonal and social protection plus approach to meet the challenges of the COVID-19 syndemic: cash transfers and intimate partner violence interventions in Latin America](#)

Merike Blofield, et al.

Lancet Infectious Diseases

Jan 2022 Volume 22 Number 1 p1-150, e1-e40

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

[Emerging SARS-CoV-2 variants: shooting the messenger](#)

The Lancet Infectious Diseases

Comment

[Ebola vaccines for mass immunisation in affected regions](#)

Selidji Todagbe Agnandji, Marguerite Massinga Loembe

Articles

[Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study](#)

Michela Antonelli, et al.

[Bell's palsy following vaccination with mRNA \(BNT162b2\) and inactivated \(CoronaVac\) SARS-CoV-2 vaccines: a case series and nested case-control study](#)

Eric Yuk Fai Wan, et al.

[Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial](#)

Vivek Shinde, et al.

[Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial](#)

David Ishola, et al. on behalf of the EBL3001 study group

[Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial](#)

Muhammed O Afolabi, et al. on behalf of the EBL3001 study group

Lancet Public Health

Jan 2022 Volume 7 Number 1 e1-e92

<https://www.thelancet.com/journals/lanpub/issue/current>

Articles

[The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries](#)

Melinda C Mills, Tobias Rüttenauer

Viewpoint

[Safeguarding people living in vulnerable conditions in the COVID-19 era through universal health coverage and social protection](#)

Gabriela Cuevas Barron, for the Lancet Commission on COVID-19: Task Force on Humanitarian Relief, Social Protection and Vulnerable Groups

Lancet Respiratory Medicine

Jan 2022 Volume 10 Number 1 p1-120, e1-e10

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 25, issue 12, December 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 42 Issue 1, January 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 4 Pages: 853-1206 December 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

Nature

Volume 601 Issue 7891, 6 January 2022

<https://www.nature.com/nature/volumes/601/issues/7891>

[New issue; No digest content identified]

Nature Biotechnology

Volume 39 Issue 12, December 2021

<https://www.nature.com/nbt/volumes/39/issues/12>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 08 Jan 2022)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 12, December 2021

<https://www.nature.com/ng/volumes/53/issues/12>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 12, December 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/12>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 12, December 2021

<https://www.nature.com/nm/volumes/27/issues/12>

[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 1, January 2022

<https://www.nature.com/nrg/volumes/23/issues/1>

Review Article | 06 August 2021

[Gene drives gaining speed](#)

In this Review, Ethan Bier discusses how several impactful technical advancements, particularly involving CRISPR-based methods, are providing a diverse toolkit of gene-drive systems for the control of populations such as insect vectors of disease.

Ethan Bier

Nature Reviews Immunology

Volume 22 Issue 1, January 2022

<https://www.nature.com/nri/volumes/22/issues/1>

Review Article | 17 May 2021

[Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms](#)

This Review discusses evidence from clinical studies and animal models regarding the effects of the gut microbiota on modulating immune responses to vaccination as well as the immunological mechanisms that potentially mediate these effects.

David J. Lynn, Saoirse C. Benson, Bali Pulendran

Review Article | 17 May 2021

[Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms](#)

This Review discusses evidence from clinical studies and animal models regarding the effects of the gut microbiota on modulating immune responses to vaccination as well as the immunological mechanisms that potentially mediate these effects.

David J. Lynn, Saoirse C. Benson, Bali Pulendran

Nature Reviews Drug Discovery

Volume 21 Issue 1, January 2022

<https://www.nature.com/nrd/volumes/21/issues/1>

Comment | 29 July 2021

Therapeutic genome editing: regulatory horizons

An increasing number of genome-editing technologies are being developed. Here, we highlight some of the key issues for future therapies using these technologies from a regulatory perspective.

Philip A. Hines, Eleonora Agricola, Ralf Herold

New England Journal of Medicine

January 6, 2022 Vol. 386 No. 1

<http://www.nejm.org/toc/nejm/medical-journal>

Original Articles

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

E.B. Walter and Others

Pediatrics

Volume 149, Issue 1 January 2022

<https://pediatrics.aappublications.org/>

Articles

Spatial Clustering of Vaccine Exemptions on the Risk of a Measles Outbreak

Ashley Gromis, PhD; Ka-Yuet Liu, DPhil

Enteropathogen Changes After Rotavirus Vaccine Scale-up

Sarah-Blythe Ballard, MD; David Requena, MSc; Holger Mayta, PhD; Gerardo J. Sanchez, MSc; Maria G. Oyola-Lozada, MSc ...

Commentaries

Vaccine Exemptions and the Risk of Continued Disease Outbreaks

Yvonne A. Maldonado, MD; Sean O'Leary, MD, MPH; Peter Hotez, MD, PhD, DSc (hon)

From the American Academy of Pediatrics

Policy Statement

COVID-19 Vaccines in Children and Adolescents

Committee on Infectious Diseases

Pediatrics Perspectives

Proposals to Accelerate Novel Vaccine Development for Children

Sallie Permar, MD, PhD; C. Buddy Creech, MD, MPH; Kathryn M. Edwards, MD; Emmanuel B. Walter, MD, MPH

PharmacoEconomics

Volume 39, issue 12, December 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-12>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 08 Jan 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 08 Jan 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 08 Jan 2022)

[Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study](#)

Jonathon W. Senefeld, Patrick W. Johnson, Katie L. Kunze, Evan M. Bloch, Noud van Helmond, Michael A. Golafshar, Stephen A. Klassen, Allan M. Klompas, Matthew A. Sexton, Juan C. Diaz Soto, Brenda J. Grossman, Aaron A. R. Tobian, Ruchika Goel, Chad C. Wiggins, Katelyn A. Bruno, Camille M. van Buskirk, James R. Stubbs, Jeffrey L. Winters, Arturo Casadevall, Nigel S. Paneth, Beth H. Shaz, Molly M. Petersen, Bruce S. Sachais, Matthew R. Buras, Mikolaj A. Wiczorek, Benjamin Russoniello, Larry J. Dumont, Sarah E. Baker, Ralph R. Vassallo, John R. A. Shepherd, Pampee P. Young, Nicole C. Verdun, Peter Marks, N. Rebecca Haley, Robert F. Rea, Louis Katz, Vitaly Herasevich, Dan A. Waxman, Emily R. Whelan, Aviv Bergman, Andrew J. Clayburn, Mary Kathryn Grabowski, Kathryn F. Larson, Juan G. Ripoll, Kylie J. Andersen, Matthew N. P. Vogt, Joshua J. Dennis, Riley J. Regimbal, Philippe R. Bauer, Janis E. Blair, Zachary A. Buchholtz, Michaela C. Pletsch, Katherine Wright, Joel T. Greenshields, Michael J. Joyner, R. Scott Wright, Rickey E. Carter, DeLisa Fairweather

Research Article | published 20 Dec 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003872>

[Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study](#)

Mie Agermose Gram, Jens Nielsen, Astrid Blicher Schelde, Katrine Finderup Nielsen, Ida Rask Moustsen-Helms, Anne Katrine Bjørkholt Sørensen, Palle Valentiner-Branth, Hanne-Dorthe Emborg

Research Article | published 17 Dec 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003874>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 08 Jan 2022)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 08 Jan 2022]

Research Article

[Characteristics of severely malnourished under-five children immunized with Bacillus Calmette-Guérin following Expanded Programme on Immunization schedule and their outcomes during hospitalization at an urban diarrheal treatment centre, Bangladesh](#)

Mst. Mahmuda Ackhter, Abu Sadat Mohammad Sayeem Bin Shahid, Tahmeed Ahmed, Parag Palit, Irin Parvin, Md. Zahidul Islam, Tahmina Alam, Shamsun Nahar Shaima, Lubaba Shahrin, Farzana Afroze, Monira Sarmin, Shoeb Bin Islam, Zubair Akhtar, Mohammad Jobayer Chisti, Fahmida Chowdhury

Research Article | published 07 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262391>

[The social specificities of hostility toward vaccination against Covid-19 in France](#)

Nathalie Bajos, Alexis Spire, Léna Silberzan, for the EPICOV study group

Research Article | published 06 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262192>

[Immunogenicity and waning immunity from the oral cholera vaccine \(Shanchol™\) in adults residing in Lukanga Swamps of Zambia](#)

Harriet Ng'ombe, Michelo Simuyandi, John Mwaba, Charlie Chaluma Luchen, Peter Alabi, Obvious Nchimunya Chilyabanyama, Cynthia Mubanga, Luiza Miyanda Hatyoka, Mutinta Muchimba, Samuel Bosomprah, Roma Chilengi, Geoffrey Kwenda, Caroline Cleopatra Chisenga

Research Article | published 05 Jan 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262239>

[Active pro-vaccine and anti-vaccine groups: Their group identities and attitudes toward science](#)

Józef Maciuszek, Mateusz Polak, Katarzyna Stasiuk, Dariusz Doliński

Research Article | published 30 Dec 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0261648>

[Changes in attitudes to vaccination as a result of the COVID-19 pandemic: A longitudinal study of older adults in the UK](#)

Allyson J. Gallant, Louise A. Brown Nicholls, Susan Rasmussen, Nicola Cogan, David Young, Lynn Williams

Research Article | published 23 Dec 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0261844>

[Assessing vaccination priorities for different ages and age-specific vaccination strategies of COVID-19 using an SEIR modelling approach](#)

Cong Yang, Yali Yang, Yang Li

Research Article | published 22 Dec 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0261236>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 08 Jan 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

December 14, 2021; vol. 118 no. 50

<https://www.pnas.org/content/118/50>

[New issue: No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 153 December 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/153/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

12 January 2022 Volume 289 Issue 1966

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 202 Pages 1-138 (January 2022)

<https://www.sciencedirect.com/journal/public-health/vol/202/suppl/C>

Editorial Full text access

[COVID-19 vaccine dilemmas](#)

A.C.K. Lee, J.R. Morling

Review article Abstract only

[Incidence of infectious diseases after earthquakes: a systematic review and meta-analysis](#)

Sara Najafi, Arash Akahavan Rezayat, Seyyedeh Faezeh Beyzaei, Zahra Shahriari, ... Ramin Hamidi Farahani

Pages 131-138

Research article Full text access

[COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey \(CoVAccS – wave 2\)](#)

S.M. Sherman, J. Sim, M. Cutts, H. Dasch, ... L.E. Smith

Public Health Ethics

Volume 14, Issue 3, November 2021
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Reports

Volume 136 Issue 6, November/December 2021
<https://journals.sagepub.com/toc/phrg/136/6>
[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 2, January 2022
<https://journals.sagepub.com/toc/ghra/current>
Research Articles

[Unvaxxed: A Cultural Study of the Online Anti-Vaccination Movement](#)

Carlina DiRusso, Kathleen Stansberry
First Published November 30, 2021; pp. 317–329

Research Ethics

Volume 18 Issue 1, January 2022
<http://journals.sagepub.com/toc/reab/current>
[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 08 Jan 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>
Selected Articles

28 Dec 2021

[COVID-19 and inequities in the Americas: lessons learned and implications for essential health services](#)

Opinion and analysis | English |

27 Dec 2021

[Response to the COVID-19 Pandemic in Chile, Colombia, and Peru from a children's rights perspective](#)

Original research | Spanish |

Risk Analysis

Volume 41, Issue 11 Pages: 1957-2176 November 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 08 Jan 2022]

Original Research

[Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis](#)

Mahallawi WH, Ibrahim NA, Mumena WA

Published Date: 30 December 2021

Science

Volume 375| Issue 6576| 7 Jan 2022

<https://www.science.org/toc/science/current>

Feature

[The pandemic whistleblower](#)

BY Jon Cohen

06 Jan 2022: 16-19

Rick Bright raised the alarm about the Trump administration's response to COVID-19. Now, he wants to build an alert system for future threats

Policy Forum

[Eroding norms over release of self-spreading viruses](#)

BY Filippa Lentzos et al.

06 Jan 2022: 31-33

Risky research on lab-modified self-spreading viruses has yet to present credible paths to upsides

Science Translational Medicine

Volume 14| Issue 626| 5 Jan 2022

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 291 December 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/291/suppl/C>

[New issue; No digest content identified]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 08 Jan 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 1-2, April 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-1>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 44 November–December 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 12 Pages: i-iv, 1527-1717 December 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 51 Pages 7357-7520 (17 December 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/51>

Conference info Full text access

[Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12–13 February 2020](#)

Gerald Voss, Jeanne-Marie Jacquet, Nadia Tornieporth, Beate Kampmann, ... Mimi Darko

Pages 7357-7362

Discussion Full text access

[Vaccination of healthcare personnel in the COVID-19 era: A call for actions](#)

Helena C. Maltezou

Pages 7363-7365

Research article Abstract only

[Using the Theory of Planned behavior to identify correlates of HPV vaccination uptake among college students attending a rural university in Alabama](#)

Sayyed Fawad Ali Shah, Tamar Ginossar, Joshua M Bentley, Gregory Zimet, J. Patrick McGrail

Pages 7421-7428

Research article Open access

[Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework](#)

Colleen L. Lau, Helen J. Mayfield, Jane E. Sinclair, Samuel J. Brown, ... John Litt

Pages 7429-7440

Research article Abstract only

[Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states](#)

Lavanya Vasudevan, Jan Ostermann, Yunfei Wang, Sayward E. Harrison, ... Emmanuel B. Walter
Pages 7485-7493

Value in Health

December 2021 Volume 24 Issue 12 p1715-1870

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 08 Jan 2022]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[Monitoring/selection from medRxiv will resume in our next edition]

Wellcome Open Research [to 08 Jan 2022]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 08 Jan 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Review metrics Revised

[Rapid evidence review to inform safe return to campus in the context of coronavirus disease 2019 \(COVID-19\)](#) [version 2; peer review: 3 approved]

Trisha Greenhalgh, Aris Katzourakis, Tristram D. Wyatt, Stephen Griffin

Peer Reviewers Stefan J. Marciniak; Stephen Duckett; Michelle Ananda-Rajah

Funder Wellcome Trust

LATEST VERSION PUBLISHED 05 Jan 2022

Research Article metrics AWAITING PEER REVIEW

[The effect of introduction of routine immunization for rotavirus vaccine on paediatric admissions with diarrhoea and dehydration to Kenyan Hospitals: an interrupted time series study](#) [version 1; peer review: awaiting peer review]

Daisy Chelangat, Lucas Malla, Reuben C. Langat, Samuel Akech, Clinical Information Network Author Group

Peer Reviewers Invited

Funder Wellcome Trust

PUBLISHED 04 Jan 2022

Systematic Review metrics AWAITING PEER REVIEW

[Incentivising research data sharing: a scoping review](#) [version 1; peer review: awaiting peer review]

Helen Buckley Woods, Stephen Pinfield

Peer Reviewers Invited

Funder Wellcome

PUBLISHED 21 Dec 2021

*

*

*

*

Think Tanks

Brookings [to 08 Jan 2022]

<http://www.brookings.edu/>

Accessed 08 Jan 2022

Up Front

[Is the world now paying the price of not doing enough to help developing world COVID-19 vaccination efforts?](#)

Dany Bahar

Friday, January 7, 2022

Coronavirus (COVID-19) Health

[Vaccination in nursing homes not all about politics: An update](#)

Sarah Reber and Cyrus Kosar

Wednesday, December 22, 2021

Center for Global Development [to 08 Jan 2022]

<http://www.cgdev.org/page/press-center>

Accessed 08 Jan 2022

[Omicron, Africa, and the Need for Much Better Policy from High-Income Countries](#)

December 20, 2021

High-income countries play a key role in the global response to Omicron. Their decisions can help increase global vaccination coverage, curb the spread of current variants, and prevent the emergence of new ones. Here we outline three actions high-income countries should take to help end the pandemic sooner.

Anthony McDonnell and Javier Guzman

[Progress and Priorities in Promoting Transparency along the COVID-19 Vaccine Value Chain](#)

December 20, 2021

CGD co-hosted an [online event](#) in November with the U4 Anti-Corruption Resource Centre to discuss the progress and challenges in pursuit of a transparent and equitable roll out of COVID-19 vaccine. Following on [earlier calls](#) for transparency, this event built on [new research from U4](#) and pointed to two main areas of progress as well as two priorities going forward.
[Morgan Pincombe](#) and [Javier Guzman](#)

Chatham House [to 08 Jan 2022]

<https://www.chathamhouse.org/>

Accessed 08 Jan 2022

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 08 Jan 2022

Commentary

[World Leaders Should Acknowledge That IP Protections Facilitate Vaccine Access](#)

January 6, 2022 | By [Andrei Iancu](#)

Transcript

[A Conversation with Paul Spiegel on the Afghan Healthcare System](#)

January 3, 2022

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 08 Jan 2022

December 21, 2021 *News Release*

[Omicron Variant Increases Worries and Gives Momentum to COVID-19 Booster Shots; May Motivate a Small Share of Unvaccinated Adults to Get an Initial Shot](#)

The emergence of the omicron COVID-19 variant is encouraging many already vaccinated adults to get a recommended booster shot but is providing only a little motivation for unvaccinated adults to get an initial shot, a new KFF COVID-19 Vaccine Monitor quick response survey finds. Fielded from Dec. 15-20 to provide...

ODI [Overseas Development Institute] [to 08 Jan 2022]

<https://odi.org/en/publications/>

Publications

[No new digest content identified]

* * * *

Contents [click to move among sections]

- ::
- Milestones - Perspectives**
- :: Coronavirus [COVID-19] - WHO
- :: Emergencies
- :: Organization Announcements
- :: Journal Watch

* * * *

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *

* * * *